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Toxicity of Radiotherapy 
in Patients With Collagen 
Vascular Disease
Background
A diagnosis of collagen vascular disease (CVD) may predispose to radiotherapy (RT) toxicity. The 
objective of the current study was to identify factors that influence RT toxicity in the setting of CVD.
Methods
A total of 86 RT courses for 73 patients with CVD were delivered between 1985 and 2005. CVD 
subtypes include rheumatoid arthritis (RA; 33 patients), systemic lupus erythematosus (SLE; 13 
patients), scleroderma (9 patients), dermatomyositis/polymyositis (5 patients), ankylosing spondy-
litis (4 patients), polymyalgia rheumatica/temporal arteritis (4 patients), Wegener granulomatosis 
(3 patients), and mixed connective tissue disorders (MCTD)/other (2 patients). Each patient with 
CVD was matched to 1 to 3 controls with respect to sex, race, site irradiated, RT dose (±2 Gray), and
age (±5 years).
Results
There was no significant difference between CVD patients (65.1%) and controls (72.5%) 
experiencing any acute toxicity. CVD patients had a higher incidence of any late toxicity (29.1% vs 
14%; P = .001), and a trend toward an increased rate of severe late toxicity (9.3% vs 3.7%; P = .079). 
RT delivered to the breast had increased risk of severe acute toxicity, whereas RT to the pelvis 
had increased risk of severe acute and late toxicity. RT administered in the setting of scleroderma 
carried a higher risk of severe late toxicity, whereas RT to SLE patients carried a higher risk of 
severe acute and late toxicity.
Conclusions
Although generally well tolerated, RT in the setting of CVD appears to carry a higher risk of late 
toxicity. RT to the pelvis or in the setting of SLE or scleroderma may predispose to an even greater 
risk of severe toxicity. These issues should be considered when deciding whether to offer RT for 
these patients. Cancer 2008;113:648–53. ©2008 American Cancer Society.
Key Words: radiotherapy, collagen diseases, complications, adverse effects.
The decision of whether to offer therapeutic radiotherapy (RT) to patients with collagen vascular 
disease (CVD) continues to be a challenging one. It is believed that CVD may predispose patients 
to increased toxicity, and many practicing oncologists believe that a diagnosis of CVD is a relative 
contraindication to RT. However, to our knowledge, the available literature on this issue has been 
mixed. Early publications were largely case reports of CVD patients with increased toxicity from 
RT.1-8 However, 2 separate matched control studies failed to observe any increased risk of acute 
or late complications in patients with CVD versus patients without CVD.9,10 Other publications 
suggested that patients with nonrheumatoid arthritis CVD,11,12 or patients with specific subtypes of 
CVD, may be at increased toxicity risk.13-15 Further complicating the issue is the finding that some 
commonly prescribed medications, many of which are used in patients with CVD, may alter the 
radiation toxicity profile.16–18 The goals of this matched control study were to determine whether 
patients with CVD were at a higher risk of RT-associated toxicity compared with patients without 
CVD and to identify factors that influence radiation toxicity in the setting of CVD, with particular 
emphasis on medications (antirheumatic drugs, nonsteroidal antiinflammatory drugs [NSAIDs], statins, 
and calcium channel blockers [CCBs]) that when taken concurrently may alter radiation toxicity.
Materials and Methods
After Institutional Review Board approval, 
101 patients with a diagnosis of CVD treated 
in the Department of Radiation Oncology at 
the University of Michigan between 1985 and 
2005 were identified. A total of 116 unique 
RT courses were delivered to these patients. A 
majority of these courses were delivered with 
3-dimensional (3D) conformal techniques. 
Twenty-two cases were excluded because the 
diagnosis of CVD was made after the comple-
tion of RT. Of the remaining 94 RT courses, 8 
courses could not be matched with a control. 
This left an analyzable sample of 86 CVD RT 
courses for 73 unique patients. Thirty-three 
patients had rheumatoid arthritis (RA), 13 
had systemic lupus erythematosus (SLE), 9 
had scleroderma, 5 had dermatomyositis/poly-
myositis, 4 had ankylosing spondylitis, 4 had 
polymyalgia rheumatica/temporal arteritis, 
3 had Wegener granulomatosis, and 2 had 
mixed connective tissue disorders (MCTD)/
other. Neither polymyalgia rheumatica/tem-
poral arteritis nor Wegener granulomatosis 
are defined as a CVD; however, their inclusion 
was based on the systemic vasculitis noted with 
these diseases and its potential impact on RT 
toxicity. The mean age of the patients at time 
of RT was 58.2 years (range, 23-84 years) and 
the majority of patients were women (73.3%). 
Sixty patients received only a single RT course, 
with 13 patients receiving 2 RT courses in this 
dataset. Their medical records were reviewed 
for the following characteristics: age, sex, race, 
CVD type and activity, date of CVD diagnosis, 
concurrent medications, cancer diagnosis, 
chemotherapy treatment details, site and dose 
schedule of RT, acute and late toxicity, pattern 
of failure, and survival.
Of the total 86 RT courses, 15 were delivered 
to the thorax, 14 to the skin, 12 to the head and 
neck, 11 to bone, 11 to the pelvis, 8 to the breast, 
6 to total body, 4 to the central nervous system, 
4 to the abdomen, and 1 to an extremity. 
Each CVD patient was then matched with a 
control patient without CVD for sex, race, 
site of disease treated by RT, dose delivered
(±2 Gray [Gy]), and age at time of RT delivery
(±5 years). For CVD patients with many
matching controls, the controls with the smallest
difference with regard to RT dose and age at 
Alexander Lin, MD,1 Eyad Abu-Isa, MD,1 Kent A. Griffith, MPH, MS2
Edgar Ben-Josef, MD1
1Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. 
2University of Michigan Cancer Center Biostatistics Core, Ann Arbor, Michigan.
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RT were chosen, with importance placed on minimizing the difference in 
RT dose over the difference in age at RT. An attempt was made to find 
3 matching controls for each CVD RT course. Fifty-nine courses were 
matched to 3 controls, 18 courses were matched to 2 controls, and 9 
courses were matched to a single control.
Acute toxicity was defined as toxicity from the time of commencement of 
RT through Day 90 after treatment and was scored using the Radiation 
Therapy Oncology Group (RTOG) common toxicity criteria.19 Late 
toxicity was defined as occurring after Day 90 posttreatment, and was 
scored according to the RTOG/European Organization for Research and 
Treatment of Cancer (EORTC) late radiation morbidity scoring schema.20 
Severe acute or late toxicity was defined as ≥grade 3. 
Because this is a match-pairs, case-control analysis, conditional logistic 
regression techniques were used. Because sex, age at RT, anatomic site 
treated, and RT dose were matched for by the design, these covariates 
were not adjusted for in the modeling process because their impact has 
been adjusted for by the study design. The remaining covariates of interest 
were as follows: concurrent infusional chemotherapy administration, and 
the use of steroids, NSAIDS, statins, CCBs, antimalarial antirheumatic 
drugs, and oral cytotoxic antirheumatics. Many of the medications apply 
only to the CVD cases and could not be adjusted for in the overall model. 
The medication list is therefore most appropriately used to help predict 
toxicity in the CVD group separately. 
Overall crude rates for toxicity are reported by the anatomic site of RT 
delivery and by CVD subtype of the cases. Although these rates are 
instructive, formal comparison at the matched case-control level has not 
been attempted because of the small sample size. Formal comparisons 
were limited to the entire population. P values ≤.05 are considered 
statistically significant. 
There were 4 endpoints of interest: any acute toxicity, severe acute 
toxicity, any late toxicity, and severe late toxicity.
Results
Acute Toxicity
With a median follow-up time of 1.3 years for each group, overall, there 
was no significant difference noted with regard to the incidence of acute 
toxicity between CVD and control cases, with 65.1% of CVD patients 
experiencing any acute toxicity, compared with 72.5% of control patients 
(Table 1). The incidence of severe acute toxicity was similar in both 
groups (10.5% vs 10.4%).
Late Toxicity
Overall, patients with a CVD diagnosis had a significantly higher 
incidence of any late toxicity (29.1% vs 14%; P =.001), with a trend toward 
increased severe late toxicity (9.3% vs 3.7%; P =.079) (Table 1).          
Table 1. Acute and Late Toxicity by CVD Status
Toxicity Grade Any Severe
Frequency
(percent) 0 1 2 3 4 5 P† P†
Acute Toxicity*
  CVD cases 30 (34.9) 19 (22.1) 28 (32.6)   9 (10.5) 0 0 — —
  Control Cases 61 (27.5) 63 (28.4) 75 (33.8) 23 (10.4) 0 0 .97 .075
Late Toxicity‡
  CVD cases 61 (70.9) 10 (11.6)   7 (8.1)   4 (4.7) 2 (2.3) 2 (2.3) — —
  Control Cases 191 (86.0) 14 (6.3)   9 (4.1)    7 (3.2)  1 (0.5) 0 .0010 .079
CVD indicates collagen vascular disease.
* Acute toxicity was defined as toxicity from the commencement of radiotherapy through Day 90 after treatment, and 
was scored using the Radiation Therapy Oncology Group (RTOG) common toxicity criteria.19
† Exact P value was derived from conditional logistic regression analysis.
‡ Late toxicity was defined as that occurring after Day 90 after treatment, and was scored according to
the RTOG/European Organization for Research and Treatment of Cancer (EORTC) late radiation morbidity
scoring schema.20
Table 2. Acute and Late Toxicity by Anatomic Site of 
Radiotherapy Delivery
Frequency
(Percent) Acute toxicity grade*
0 1 2 3 4 5
Bone
  Cases (n = 11)  11 (100.0)   0   0 0 0 0
  Controls (n = 28)  20 (71.4)    4 (14.3)    4 (14.3)  0  0  0
Breast
  Cases (n = 8)    1 (12.5)    1 (12.5)    4 (50.0)  2 (25.0)  0  0
  Controls (n = 20)    0    6 (30.0)  14 (70.0)  0  0  0
Head and neck 
  Cases (n = 12)    0    4 (33.3)    6 (50.0)  2 (16.7)  0  0
  Controls (n = 32)    5 (15.6)    8 (25.0)  12 (37.5)  7 (21.9)  0  0
Pelvis 
  Cases (n = 11)    0    1 (9.1)    6 (54.6)  4 (36.4)  0  0
  Controls (n = 28)    2 (7.1)    7 (25.0)  16 (57.1)  3 (10.7)  0  0
Skin 
  Cases (n = 14)    0  10 (71.4)    4 (28.6)  0  0  0
  Controls (n = 35)    1 (2.9)  17 (48.6)  14 (40.0)  3 (8.6)  0  0
Thorax 
  Cases (n = 15)    6 (40.0)    3 (20.0)    6 (40.0)  0  0  0
  Controls (n = 41)  14 (34.2)  12 (29.3)    8 (19.5)  7 (17.1)  0  0
Other Sites† 
  Cases (n = 15)  12 (80.0)    0    3 (20.0)  0  0 0
  Controls (n = 38)  19 (50.0)    9 (23.7)    6 (15.8)  4 (10.5)  0  0
Late toxicity grade‡
0 1 2 3 4 5
Bone
  Cases (n = 11) 11 (100.0) 0 0 0 0 0
  Controls (n = 28) 27 (96.4) 1 (3.6) 0 0 0 0
Breast
  Cases (n = 8)   5 (62.5) 1 (12.5) 2 (25.0) 0 0 0
  Controls (n = 20) 13 (65.0) 4 (20.0) 3 (15.0) 0 0 0
Head and neck 
  Cases (n = 12)   6 (50.0) 2 (16.7) 2 (16.7) 2 (16.7) 0 0
  Controls (n = 32) 24 (75.0) 2 (6.3) 2 (6.3) 3 (9.4) 1 (3.1) 0
Pelvis 
  Cases (n = 11)   4 (36.4) 2 (18.2) 1 (9.1) 1 (9.1) 2 (18.2) 1 
(9.1)
  Controls (n = 28) 21 (75.0) 2 (7.1) 3 (10.7) 2 (7.1) 0 0
Skin 
  Cases (n = 14) 10 (71.4) 4 (28.6) 0 0 0 0
  Controls (n = 35) 35 (100.0) 0 0 0 0 0
Thorax 
  Cases (n = 15)  11 (73.3)  1 (6.7)  2 (13.3)  1 (6.7)  0  0
  Controls (n = 41) 36 (87.8) 4 (9.8) 1 (2.4) 0 0 0
Other Sites† 
  Cases (n = 15) 14 (93.3) 0 0 0 0 1 
(6.7)
  Controls (n = 38) 36 (94.7) 0 0 2 (5.3) 0 0
CVD indicates collagen vascular disease.
* Acute toxicity was defined as toxicity from the commencement of radiotherapy through Day 90 after treatment, 
and was scored using the Radiation Therapy Oncology Group (RTOG) common toxicity criteria.19
† Other sites included the abdomen, central nervous system, extremities, and total body.
‡ Late toxicity was defined as that occurring after Day 90 after treatment, and was scored according to the 
RTOG/European Organization for Research and Treatment of Cancer (EORTC) late radiation morbidity 
scoring schema.20
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Toxicity by Irradiated Site
Although overall there was no significant difference noted with regard 
to the incidence of acute toxicity, CVD patients treated with RT to 
some anatomic sites were found to have a higher rate of severe acute 
toxicity (Table 2). RT to CVD patients produced higher crude rates of 
grade 3 acute toxicity when delivered to the breast (2 patients [25%] 
vs 0 patients [0%]) or pelvis (4 patients [36%] vs 3 patients [11%]). 
For the 2 CVD patients with severe breast acute toxicity, toxicity 
consisted of grade 3 skin desquamation. For the 4 CVD patients with 
severe pelvic acute toxicity, 3 had grade 3 skin desquamation alone, 
whereas the fourth patient had grade 3 skin desquamation, cystitis, 
and diarrhea/dehydration. However, given the small sample sizes 
per group and the matched case-control design of the study, formal 
statistical comparisons were not attempted. 
RT to several anatomic sites produced a higher crude rate of any 
late toxicity in CVD patients (Table 2), including the head and neck
(6 patients [50%] vs 8 patients [25%]), pelvis (7 patients [64%] vs 
7 patients [25%]), skin (4 patients [29%] vs 0 patients [0%]), and 
thorax (4 patients [27%] vs 5 patients [12%]). The incidence of severe 
toxicity was greater mainly only in the pelvis subgroup, with 4 CVD 
patients (36%) experiencing grade 3+ toxicity (consisting of small bowel 
ulceration and dysuria), including 1 grade 5 event (intestinal perforation), 
versus 2 in the control group with severe toxicity (7%). RT to the other 
anatomic sites was found to be equally well tolerated by both CVD and 
control patients.
Toxicity by CVD Subtype
Table 3 summarizes the toxicity information when separated by CVD 
subtype. The only patients who had an appreciably higher crude incidence 
of any acute toxicity when compared with controls were patients with SLE 
(88.2% vs 76.2%). Patients with SLE were also the only CVD subset found 
to have a higher crude risk of severe acute toxicity (29.4% vs 11.9%), 
which was the highest rate of severe acute toxicity noted among all CVD 
subtypes. Otherwise, severe acute toxicity was uncommon. 
Compared with controls, the incidence of any late toxicity was observed 
to be higher in several CVD subtypes: RA (29.7% vs 13.9%), SLE (41.2% 
vs 19.1%), dermatomyositis/polymyositis (16.7% vs 8.3%), polymyalgia 
rheumatica/temporal arteritis (28.6% vs 5.0%), and MCTD/other (50.0% 
vs 16.7%). The incidence of severe late toxicity was generally low among 
both CVD and control patients; however, patients with SLE (35.3% vs 
4.8%) and scleroderma (10.0% vs 3.9%) had a higher risk of severe late 
toxicity versus controls.
Concomitant Medication Use by CVD Patients
Table 4 lists several types of medications and their frequencies of use 
by CVD patients. Tables 5 and 6 list the distribution of acute and late 
toxicities for CVD cases, respectively. None of the following medications 
was found to be significantly associated with a risk of any acute or late 
toxicity: corticosteroids, NSAIDs, statins, CCBs, and antimalarials. The 
use of oral cytotoxic, rheumatologic agents was found to be significantly 
associated with a decreased risk of any acute toxicity (P = .0263), and 
concurrent infusional chemotherapy was found to be significantly 
associated with an increased risk of severe acute toxicity (P = .0022). 
Chemotherapy was the only concomitant medication that was found to 
be associated with increased risk of any (P = .009) or severe (P = .009) 
late toxicity.
Discussion
Delivering RT to patients with CVD continues to be a challenging clinical 
dilemma for radiation oncologists. The existing literature is difficult to 
interpret because of the heterogeneity in CVD subtype and activity, the 
variations in RT dose and site of treatment, as well as the potential role 
of concomitant medications in altering toxicity. Morris and Powell11 
reported that severe late effects were associated with CVD other than 
Table 3. Distribution of Toxicity (Percent) by CVD Case/Control Status, by CVD Subtype
                                                       Acute*                                                                                                      Late                                           
                            Any                                            Severe                                       Any                                       Severe             
CVD Subtype CVD Control CVD Control CVD Control CVD Control
Rheumatoid arthritis  64.9  76.2  10.8  9.9  29.7  13.9  2.7  4.0
Systemic lupus erythematosus  88.2  76.2  29.4  11.9  41.2  19.1  35.3  4.8
Dermatomyositis/polymyositis  66.7  91.7  0  8.3  16.7  8.3  0  0
Ankylosing spondylitis  0 0 0 0 0 0 0 0
Wegener granulomatosis 100  100  0  16.7  33.3  33.3 0  0
Scleroderma  30.0  53.9 0  11.5  20.0  15.4  10.0  3.9
Polymyalgia rheumatica/temporal arteritis  85.7  80.0  0  10.0  28.6  5.0  0  5.0
Mixed connective tissue disorder/other  50.0  83.3  0  16.7  50.0  16.7  0  0
CVD indicates collagen vascular disease.
* Acute toxicity was defined as toxicity from the commencement of radiotherapy through Day 90 after treatment, and was scored using the Radiation Therapy Oncology Group (RTOG) common toxicity criteria.19
† Late toxicity was defined as that occurring after Day 90 after treatment, and was scored according to the RTOG/European Organization for Research and Treatment of Cancer (EORTC) late radiation morbidity
scoring schema.20
†
Table 4. Medications and Frequency of Use for CVD Patients
Cases (n = 86)
Medication Frequency Percentage
NSAIDs  34  39.5
Corticosteroids  32  37.2
Antimalarials  25  29.1
CCB  20  23.2
Chemotherapy*  18  20.9
Oral cytotoxic, antirheumatic drugs  17  19.8
Statins  13  15.1
CVD indicates collagen vascular disease; NSAIDs, nonsteroidal antiinflammatory drugs; CCB, calcium-
channel blocker.
* Concurrent with radiotherapy.
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Table 6. 
Medications and Treatments by Late Toxicity*: CVD Cases Only
Toxicity Grade Any Severe
Frequency
(percent) 0 1 2 3 4 5 P† P†
Corticosteroids
   No
   Yes
 37 (68.5)  6 (11.1)  5 (9.3)  3 (5.6)  2 (3.7)  1 (1.9)
 24 (75.0)  4 (12.5)  2 (6.3)  1 (3.1)  0  1 (3.1)  .63  .70
NSAIDS
   No
   Yes
 37 (71.2)  5 (9.6)  6 (11.5)  3 (5.8)  0  1 (1.9)
 24 (70.6)  5 (14.7)  1 (2.9)  1 (2.9)  2 (5.9)  1 (2.9)  ˜1  .71
Statins
   No
   Yes
 52 (71.2)  8 (11.0)  6 (8.2)  3 (4.1)  2 (2.7)  2 (2.7)
   9 (69.2)  2 (15.4)  1 (7.7)  1 (7.7)  0  0   ˜1  ˜1
CCB
   No
   Yes
 47 (71.2)  7 (10.6)  6 (9.1)  4 (6.1)  0  2 (3.0) 
 14 (70.0)  3 (15.0)  1 (5.0)  0  2 (10.0) 0   ˜1  ˜1
Antimalarials
   No
   Yes
 45 (73.8)  6 (9.8)  6 (9.8)  3 (4.9)  0  1 (1.6)
 16 (64.0)  4 (16.0)  1 (4.0)  1 (4.0)  2 (8.0)  1 (1.0)  .44  .22
Oral cytotoxics
   No
   Yes
 48 (69.6)  7 (10.1)  7 (10.1)  4 (5.8)  2 (2.9)  1 (1.5) 
 13 (76.5)  3 (17.6)  0  0  0  1 (5.9)  .77  ˜1
Infusional 
chemotherapy
   No
   Yes
 53 (77.9)  8 (11.8)  4 (5.9)  2 (2.9)  0  1 (1.5)
   8 (44.4)  2 (11.1)  3 (16.7)  2 (11.1)  2 (11.1)  1 (5.6)  .0087  .0089
CVD indicates collagen vascular disease; NSAIDs, nonsteroidal anti-inflammatory drugs; CCB, calcium-
channel blocker.
* Late toxicity was defined as that occurring after Day 90 after treatment, and was scored according to the RTOG/
European Organization for Research and Treatment of Cancer (EORTC) late radiation morbidity scoring schema.20
† P value was derived using the Fisher exact test.
Table 5. 
Medications and Treatments by Acute Toxicity*: CVD Cases Only
Toxicity Grade Any Severe
Frequency
(percent) 0 1 2 3 P† P†
Corticosteroids
   No
   Yes
  22 (40.7)  11 (20.4)  14 (25.9)  7 (13.0)
    8 (25.0)    8 (25.0)  14 (43.8)  2 (6.3)  .17 .47
NSAIDS
   No
   Yes
 17 (32.7)  11 (21.2)  18 (34.6)  6 (11.5)
 13 (38.2)    8 (23.5)  10 (29.4)  3 (8.8) .65 ˜1
Statins
   No
   Yes
 28 (38.4)  13 (17.8)  23 (31.5)  9 (12.3)
   2 (6.7)    6 (46.2)    5 (38.5)  0  .13  .34
CCB
   No
   Yes
 23 (34.9)  15 (22.7)  21 (31.8)  7 (10.6)
   7 (35.0)    4 (20.0)    7 (35.0)  2 (10.0) ˜1 ˜1
Antimalarials
   No
   Yes
 24 (39.3)  13 (21.3)  19 (31.2)  5 (8.2)
   6 (24.0)    6 (24.0)    9 (36.0)  4 (16.0)   .22  .44
Oral cytotoxics
   No
   Yes
 20 (29.0)  16 (23.2)  25 (36.2)  8 (11.6)
 10 (58.8)    3 (17.7)    3 (17.7)  1 (5.9) .026  .68
Infusional 
chemotherapy
   No
   Yes
 23 (33.8)  19 (27.9)  23 (33.8)  3 (4.4)
   7 (38.9)    0    5 (27.8)  6 (33.3)  .78  .0022
CVD indicates collagen vascular disease; NSAID, nonsteroidal anti-inflammatory drug; CCB, calcium-
channel blocker.
* Acute toxicity was defined as toxicity from the commencement of radiotherapy through Day 90 after treatment, 
and was scored using the Radiation Therapy Oncology Group (RTOG) common toxicity criteria.19
† P value was derived using the Fisher exact test.
RA, a finding that was also supported by a meta-analysis by Chon and 
Loeffler.12 Other studies suggest that a diagnosis of scleroderma13,14 or 
lupus15 may increase the risk of RT associated toxicity. However, 2 separate 
matched control studies failed to observe any increased risk of acute or
late complications in patients with CVD versus patients without CVD.9,10 
To our knowledge, the current study is the largest matched-control 
analysis of acute and late complications in patients with CVDs receiving 
RT. Unlike the other matched control studies,9,10 we did find that a 
diagnosis of a CVD increased the risk of having any late toxicity, with a 
trend toward increased severe late toxicity. We also examined a variety 
of factors that can potentially influence the toxicity profile. We found 
that there was little difference in toxicity profile for most irradiated 
sites. However, RT to the breast and pelvis were possible exceptions. 
Greater than one-third of all patients with RT to the pelvis experienced 
severe acute and late toxicity. Similar to previous studies,11–15 we also 
found that patients with scleroderma or SLE were at the highest risk 
of experiencing severe acute or late complications. Morris and Powell11 
previously examined the impact of various medications on RT toxicity 
and found that patients undergoing NSAID therapy at the time of RT 
had a lower risk of late effects. Our findings demonstrated that most 
commonly used medications did not influence RT toxicity, but that 
concurrent chemotherapy was associated with increased severe acute 
and late toxicity.
There are strengths and limitations to the current study. Similar to 
previous publications on the subject, we were limited by the heterogeneity 
of CVD subtype, which thereby limited the number of patients analyzed 
for each subtype. Toxicity data was collected retrospectively, and there 
was no reliable method with which to assess CVD activity status at the 
time of RT. We were unable to analyze dose independently as a variable. 
Because dose was dependent on treatment site, it would require a range 
of RT doses at a given site and a reasonable sample size to make dose-
specific comments. This was beyond the scope of our institutional patient 
experience. The strengths of this study lie in the total number of patients 
analyzed and the use of a 3:1 control:case match by age, sex, RT dose, and 
anatomic site. This approach allows for a more robust analysis of the risk 
profile, allowing us to determine that patients with scleroderma and SLE 
are at increased risk of severe toxicity. Although other CVD subtypes may 
also predispose to toxicity, the same conclusions cannot be made because 
of the limited sample size of patients with these subtypes in our study. It 
is also important to note that with a median follow-up of 1.3 years, the 
toxicity rates reported in our study may be underestimating the true rate 
of late toxicity. Another unique aspect of this study is the comprehensive 
analysis of concomitant medication use and its impact on the RT toxicity 
profile. Given the heterogeneity observed in CVD subtype and disease 
activity, and other variables such as RT dose and site, it is not likely that 
we will ever have prospective controlled data for these questions.
In summary, although a diagnosis of a CVD appears to predispose patients 
to a greater risk of late RT toxicity, treatment is generally well tolerated, 
with a relatively low incidence of severe acute or late toxicity. Other factors 
can impact the risk of toxicity, including CVD subtype, site of irradiation, 
RT dose, and the use of concurrent chemotherapy. In patients who may 
be at particularly high risk because of CVD subtype or RT site, careful 
attention to issues of toxicity is required. Treatment modifications such as 
reduction of fraction size, twice-daily treatment, or reduction of total dose 
for these patients may be considered. These factors should be taken into 
consideration in the risk-benefit analysis at the time of consultation.
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A Cone Beam CT-Based Study For Clinical 
Target Definition Using Pelvic Anatomy 
During Post-Prostatectomy Radiotherapy 
Introduction
Radiation therapy (RT) is delivered after radical prostatectomy (RP) either as salvage treatment for 
an elevated prostate-specific antigen (PSA) level1-6 or as adjuvant therapy for patients with high-
risk pathologic features7-8. Recent prospective data demonstrated a disease-free survival benefit 
of adjuvant RT for pathologic T3N0 prostate cancer9-10. Despite literature supporting the delivery 
of post-RP RT to the prostatic fossa (PF), no clear target definition guidelines exist for intensity 
modulated radiation therapy (IMRT) or image-guided RT (IGRT)11.
Visualization of the PF is limited on standard CT images, with significant interobserver variability 
and uncertainty in CTV definition12.  Efforts to incorporate complementary imaging modalities 
such as MRI for PF target volume definition have generated neither demonstrably more reliable 
PF delineation, nor practical contouring guidelines13. Regardless of the imaging modality, direct 
visualization and delineation of the PF clinical target volume (CTV) is fraught with uncertainty. 
On the other hand, it is possible to distinguish the borders of important nearby pelvic structures, 
namely the bladder and the rectum. The reliability of rectal volume definition on helical CT is 
supported by analysis of rectal contours defined in a prospective trial, suggesting the feasibility 
of rectal dose-volume data collection in a multicenter setting14. Fiorino et al have described a 
correlation between PF CTV shift and anterior rectal wall shift for the cranial half of the rectum in 
their report of rectal and bladder movement during post-RP RT using weekly CT images15. These 
studies support the reliability of CT-defined rectum contours and a limited correlation between PF 
CTV and anterior rectal wall, an important tenet in the current study.
The data reported by Fiorino et al. are limited by the infrequency of image collection and the 
acquisition of images at a time and place separate from the treatment couch. Though PTV margin 
recommendations are not provided by Fiorino et al., they state eloquently that 1), the anterior-
posterior movements of rectum and bladder are more important than lateral motion; 2), the rectum 
trends anteriorly during an RT course; 3), there is significant correlation between the posterior 
CTV border and the anterior rectal wall for the cranial half of the rectum15.  Through the use 
of CBCT images obtained during post-prostatectomy RT, the interfraction movement of the 
dose-limiting pelvic organs may be characterized further. This information may be used for the 
careful extrapolation of information regarding motion of the PF target volume.  Prior reports have 
described the utility of online CBCT imaging during definitive, primary RT for prostate cancer 
using equipment similar to that utilized in the current study16.  
In our study, we approach the problem of PF target definition through analysis of real-time 
CBCT images during post-RP RT, studying the motion of the critical normal tissue structures 
that approximate the anterior and posterior anatomical boundaries of the prostatic fossa.  Cone-
beam CT images, obtained during a definitive course of RT, provided information regarding rectal 
and bladder movement. For the purpose of estimating appropriate anterior and posterior PF PTV 
definition guidelines, the posterior bladder border and the anterior rectum border were considered 
as radiographic surrogates for the anterior and posterior PF borders, respectively.
Methods and Materials
The pelvic anatomy of 10 consecutive prostate cancer patients undergoing post-RP RT was studied 
retrospectively using CBCT images obtained during the course of treatment.  All patients received a
 
radiation dose of 68.4 Gy (1.8 Gy/fraction), 
delivered with a four-field conformal RT 
plan. Planning CT (CTref) scans, with 3 mm 
slice thickness, were obtained in the supine 
position with contrast dye cystograms and 
urethrograms.  Patients were instructed to 
follow a strict preparatory regimen before 
the CTref and during RT in order to ensure 
consistent filling and emptying of the bladder 
and rectum, respectively. The attending 
physician (R.V.) reviewed and approved 
CTV, rectum, and bladder CTref volumes 
on the helical CT scans for each patient as 
a component of standard RT planning and 
delivery. At our institution, a standard 1.0 cm 
PTV margin is added to the prostatic fossa 
CTV, an empirically chosen guideline.  The 
standard post-RP treatment policy in our 
department includes at least every-other-day 
CBCT scans for position verification, with 
corrective shifts for 5 mm or more. Image 
registration using CBCT scans is performed 
based upon bony anatomy including femoral 
heads, pubic arch, sacrum, ischium and ilium. 
CBCT images were obtained 2-5 times weekly 
immediately before treatment using the Elekta 
Synergy® cone beam system.  
CBCT scans (exported with a 1 mm slice thick-
ness) were registered in relation to the planning 
CT using the mutual information algorithm on 
the CMS FocalSim®. The automatically co-reg-
istered images were evaluated for accuracy by 
a single observer (T.S.); manual adjustments 
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Bladder
SUP
MID
INF
Figure 1. Rectum and bladder motion 
were recorded at three points along the 
distance from seminal vesicle stump to 
bladder-urethral junction.
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were made when necessary to produce an optimal fusion of images in 
relation to the bony pelvic anatomy. The same observer contoured blad-
der and rectal volumes on all CBCT images of satisfactory quality for 
the identification of the rectal and bladder borders. Rectal and bladder 
motion was measured from the seminal vesicle stump (SVS) to the blad-
der-urethral junction (BUJ) (Figure 1). This region was chosen since 
it represents the volume at risk for subclinical disease and it includes 
the relevant, potentially dose-limiting organs-at-risk (OAR). For each 
patient, 3 cross-sectional levels were studied: 1) superior (SUP), one slice 
caudal to the SVS; 2) inferior (INF), one slice cranial to the BUJ; and 
3) middle (MID), midway between SUP and INF levels. In the cross-
sectional plane, midsagittal coordinates were measured at the anterior 
rectal border and the posterior bladder border and compared to the plan-
ning CT volumes and the mean organ position to obtain interfraction 
motion. Lateral shifts were not assessable with this technique, and were 
not studied due to minimal impact on RT dose delivered to adjacent 
organs at risk (bladder and rectum) relative the anterior and posterior 
shifts. Inter-organ distance (IOD), the midsagittal difference between 
bladder and rectum, was also recorded at each measurement level, as this 
quantity may approximate crudely the anteroposterior PF distance. Data 
regarding organ volume and movement were collected for each CTref and 
CBCT. The mean and the standard deviation of organ border motion 
were calculated relative to both CTref and mean organ position.
In order to assess the reproducibility of the rectum and bladder by volume 
definition, repeat contours of the rectum and bladder were performed for 2 
patients. In separate contouring sessions, the same observer (T.S.) repeated 
the organ definition steps using all CBCT scans for both patients. Repeat 
measurements of the anterior rectal border and the posterior bladder 
border were recorded, and movement relative to CTref was collected. The 
difference between the two sets of CBCT organ contours was calculated 
to determine the intraobserver variability for bladder and rectum 
motion measurements. A similar process was followed for rectum and 
bladder volume measurements to determine intraobserver variation in 
organ volume. 
Anterior and posterior PTV margins were calculated by applying a for-
mula (2Σ + 0.7σ) that includes systematic error (Σ) and random error (σ) 
of target volume position17, using measured organ border shifts relative to 
CTref for each CBCT scan. Interfraction motion of the posterior bladder 
border and the anterior rectum border were used in the analysis as substi-
tutes for anterior and posterior PF motion in order to calculate estimated 
margin recommendations.
Results
Ten patients undergoing prostatic fossa RT to 68.4 Gy in 38 fractions were 
evaluable for this study.  Demographic data is displayed in Table 1. A total of 
176 CBCT study sets obtained 3-5 times weekly were analyzed. The rectal 
and bladder borders were reliably identified in 166 of 176 (93%) of CBCT 
images. Figure 2 shows a representative CBCT image. Figure 3 contains a 
typical CT image obtained for planning purposes. 
Validation of Methods
Repeat contours and measurements for two patients reveal an average 
organ movement measurement discrepancy between contour sets of 1.2 ± 
1.7 mm for bladder and 1.1 ± 1.0 mm for rectum for each of thirty CBCT 
Figure 2. Representative cone-beam CT scan obtained on the 
treatment couch immediately prior to RT.
Figure 3. Sample treatment planning CT scan (CTref) obtained 
prior to initiation of RT.
Table 1. Characteristics of 10 patients receiving 
radiotherapy to PF after radical prostatectomy
Age (years)
 Mean
 Range
 
 57
 44-69
Time from surgery to RT
 Median (months)
 ≤ 9 months (n)
 > 9 months (n)
 8.2
 6
 4
Pre-RT PSA (n)
 ≤ 0.4
 > 0.4
 6
 4
Gleason Score (n)
 GS = 6
 GS = 7
 2
 8
Pathologic Tumor Stage (n)
 pT2
 pT3
 5
 5
Extracapsular extension (n)   
 Yes
 No
 6
 4
Margin status
 Positive
 Negative
 4
 6
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study sets analyzed.   Average variation at SUP, MID, and INF levels for 
bladder was 1.0 ± 1.4 mm, 1.0 ± 1.3 mm, 1.5 ± 2.5 mm, and, for rectum, 1.1 
± 1.2 mm, 1.1 ± 0.8 mm, and 1.1 ± 1.1 mm, respectively.  Mean difference 
in bladder volume between the CBCT contours was 2.4 mL (2.6% of mean 
organ volume); for rectal volume, 2.5 mL (4.6% of mean organ volume).
Organ Motion
There was a tendency towards posterior movement of the anterior rectal 
wall and anterior tendency in the position of the posterior bladder border 
during the RT course relative to the CTref. Organ border motion values at 
SUP, MID, and INF levels are displayed in Table 2. The calculated poste-
rior margin for PF PTV creation ranged from 8.6 to 10.2 mm, while the 
calculated anterior margin for PF PTV ranged from 5.9 to 7.1 mm (Table 
2). The mean IOD observed on CTref images was 8.0 ± 5.7 mm, 6.8 ± 
5.1 mm, and 5.6 ± 3.5 mm for the SUP,MID and INF levels, respectively. 
The average CBCT IOD, based on mean IOD for all patients, was 11.4 
± 6.7 mm, 9.4 ± 3.1 mm, and 10.4 ± 4.2 mm for the SUP, MID and INF
levels, respectively.
Organ Volume
The bladder and rectum CBCT volumes measured during the course of 
RT were smaller than those obtained on the planning CT. The average 
CTref rectum volume was 67.6 ± 50.5 mL , while the average CBCT volume 
was 59.5 ± 11.3 mL (8.1 mL difference). For the bladder, the average CTref 
volume was 152.3 ± 103.3 mL, while the average CBCT volume was 93.1 
± 26.8 mL (59.2 mL difference). When patients with greater than 50% 
difference between CTref and average CBCT organ volume were removed 
from analysis (2 patients for bladder and 2 patients for rectum), the mean 
difference between average CTref and CBCT volumes decreased to 2.9 mL 
for rectum and to 40.7 mL for bladder.
Volume and Motion Relationships
Pearson correlation coefficients were calculated to analyze interrelation-
ships among mean organ motion at SUP, MID, and INF levels, as well as 
the average of all levels, mean organ volume, and mean IOD. Correla-
tion coefficient values are displayed in Table 3, revealing that the largest 
correlation exists between the anterior rectum border position and the 
distance between the rectum and bladder, with a correlation coefficient 
of 0.71 between the average interorgan distance and the average rectal wall 
position. Figure 4 displays the relationship between rectal motion and 
rectal volume.
Discussion
The normal tissue anatomy (bladder and rectum) adjacent to the PF CTV 
was readily definable throughout the course of post-RP RT using CBCT. 
Relative to the planning CT, a mean posterior shift of the anterior rectal 
wall was observed on the CBCT images.  The mean rectal volume as con-
toured on CBCT images during RT was less than the mean CTref volume. 
The rectum border shift and rectal volume change noted in this study 
may be related to a trend towards reduced rectal volume over time during 
prostate RT18-19.  Our adjusted analysis of rectum volumes, which showed 
smaller mean variations in rectum volume after the removal of two 
large, outlying values, suggests that strict adherence to the bowel prepa-
ratory regimen may produce a planning CT that is more representative 
of the rectum during RT.  The recommendation that patients in the 
current study present to clinic for RT with a full bladder and an evacu-
ated rectum may have contributed to the small level of rectum volume
variation observed.
In their study of nine patients receiving weekly CT scans during post-
RP RT, Fiorino et al report a mean anterior shift of the anterior rectal 
wall throughout the cranial half of the rectum, but no shift within the 
caudal half of the rectum15. In our study, measurements of rectum and 
Table 2. Organ motion and suggested margin guidelines 
based on systematic and random error.
Observed Motion Bladder Motion
(mm)
Rectal Motion
(mm)
Relative to  Mean SUP MID INF SUP MID INF
       CTref    SD
 (+ = anterior, 
   – =  posterior)
 +0.1 +0.4 +1.5 -2.6  -1.6 -2.7
 4.4    3.7    4.0  6.0 6.3  5.8
Relative to  Mean
mean organ    SD
position for
all scans
(absolute 
values) 
 3.3   2.9   3.1  4.7 4.8 4.5
 2.9   2.4   2.9  4.6 4.4 4.6
Systematic Error (Σ)  2.4 2.1  2.1 3.5    3.5 3.1
Random Error (Σ)  3.3 2.8 2.4 4.0    4.5 3.5
Calculated PTV 
Margin (2Σ + 0.7Σ)
 7.1 6.2 5.9 9.8 10.2 8.6
Table 3. Pearson correlation coefficients among 
mean organ motion and mean organ volume.
Bladder
Volume
Rectum 
Volume IOD
Rectum
Motion
Rectum Motion
 SUP
 MID
 INF
 AVG
 -0.15 0.37 -0.68  X
 -0.01 0.25 -0.56  X
 -0.05 0.29 -0.69  X
 -0.07 0.33 -0.71  X
Bladder Motion
 SUP
 MID
 INF
 AVG
 -0.14 0.18 0.29 0.42
 -0.14 0.17 0.18 0.43
 -0.06 0.11 0.44 0.23
 -0.12 0.18 0.10 0.45
IOD
 SUP
 MID
 INF  
 AVG
 0.04 -0.26  X  X
 -0.07 -0.21  X  X
 0.01 -0.26  X  X
 0.01 -0.28  X  X
Figure 4. Scatter plot of rectum motion and change in rectum volume.
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bladder shifts were performed only at levels that included the PF CTV. 
The mean posterior shift of the anterior rectum wall relative to CTref 
in the current study (1.6-2.7 mm) was small. The standard deviation 
of the rectal wall position on CBCT relative to the CTref (5.8-6.3 mm) 
demonstrates important interfraction variation in rectal wall position, 
noted throughout the region of rectum relevant to the PF CTV, despite 
the small average shift observed. Variations in rectal volume appear to 
impact the position of the anterior rectum wall (Figure 4). In addition, 
the interorgan distance, which may serve as a rough approximation of the 
prostatic fossa, correlates more strongly with anterior rectal motion than 
with other factors (Table 3), supporting the influence of rectal border 
motion on PF CTV delineation.
We recommend the use of a nonuniform margin for PTV definition, 
consisting of a 5.9 to 7.1 mm bladder border margin and an 8.6 to 10.2 
mm rectal border margin. A published report of significant correlation 
between the anterior rectal wall and the prostatic fossa CTV supports, in 
part, the rationale of the current study’s approach, though the reported 
relationship between rectal and CTV motion occurred only with the 
cranial portion of the rectum15. Although the influence of OAR motion 
on PF PTV margin definition seems sensible, the extrapolation of target 
information from organ motion should be approached with caution. 
The use of 3D conformal RT after RP has been shown to reduce toxicity 
relative to conventional delivery techniques20. In addition, rectal dose-
volume histograms (DVHs) for patients undergoing post-RP RT have 
been shown to correlate significantly with risk for late complications21. 
Retrospective analyses of patients undergoing salvage post-RP RT sug-
gest a benefit from RT doses 64.8 Gy or higher2-3. As higher RT doses 
are delivered to the prostatic fossa, the ability to minimize toxicity of 
adjacent tissues rests upon an understanding of motion of both CTV 
and OARs during treatment. Intensity-modulated radiation therapy 
(IMRT) may allow safe dose-escalation for post-RP RT22, but its appli-
cation requires detailed target definition guidelines1. CBCT may allow 
tighter RT margins when used to conduct IGRT with daily corrections16, 
potentially allowing for higher total doses without parallel increases in 
OAR dose and treatment-related toxicity.
The current study provides approximate anterior and posterior margins 
for PF PTV definition based on calculations using pelvic organ motion 
information. Lateral margins were not calculated, as lateral movement is 
less significant than anteroposterior motion9 and is unlikely to influence 
dose delivered to the adjacent organs at risk (bladder and rectum). Due to 
uncertainty in direct definition of the PF CTV, an indirect approach was 
utilized based on interfraction rectal and bladder motion. This approach 
acknowledges the uncertainty of CTV definition12, 23 while incorporating 
the additional anatomic information provided by on-line CBCT imaging 
during the RT course. The bladder and the rectum were easily identified 
on most CBCT images in the current study. A small number of CBCT 
images collected in the current study (7%) were unusable for organ defi-
nition due to poor image quality, which may be attributed to technical 
errors in image acquisition. The use of bladder and rectum movements 
as determinants for PTV margin guidelines may provide a reliable 
approach, as rectal contouring has been shown to be reproducible using 
helical CT scans14. These data and similar future studies should be pur-
sued to better define target-definition guidelines for post-RP conformal 
RT. Avenues for future applications of CBCT images in post-RP RT may 
include daily online localization with manual soft-tissue registration and 
subsequent corrective shifts in patient position, as well as off-line adap-
tive RT based upon a set of CBCT scans obtained during the first week 
of RT in a fashion similar to that described previously by Yan et al24. The 
current work may be used in future attempts to develop off-line adaptive 
strategies for RT that rely upon conformal avoidance of the rectum and 
bladder to target the PF CTV for post-prostatectomy patients. 
In conclusion, normal tissue anatomy (bladder and rectum) used to define 
the anterior and the posterior border of the prostatic fossa was read-
ily definable by CBCT imaging throughout the course of post-RP RT. In 
the absence of direct, target-based treatment guidelines available, CBCT 
definition of bladder and rectum volumes may be used to pursue anterior 
and posterior PTV margin recommendations.
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Inhibition of VEGF activity or disabling the 
function of VEGF receptors is therefore a 
potential strategy for improving radiation 
outcome. The VEGF blockade alone has been 
shown to inhibit both tumor growth and 
metastasis in a variety of animal tumor mod-
els11. Currently, three approaches are in clinical 
development to target the VEGF/VEGFR-sig-
naling pathway: (1) monoclonal antibodies 
directed against VEGF or its receptors12–15, 
(2) small molecule inhibitors of the VEGFR-
2 tyrosine kinase enzyme16–19, and (3) soluble 
decoy receptors created from the VEGFR1 
receptor which selectively inhibit VEGF20, 21. 
The relative benefits of these strategies have yet 
to be determined clinically.
Tumor cures are rare when VEGF blockers 
are used as the sole method of treatment; in 
general, antiangiogenics appear to work best 
in combination with cytotoxic therapies22. 
A number of preclinical studies suggest that 
radiotherapy in combination with VEGF
targeting agents enhances the radiotherapeutic 
ratio (see reviews;23, 24). The best way to incor-
porate VEGF inhibition strategies into current 
radiotherapy regimens remains unknown.
Because of the role that angiogenesis plays in 
the radiation response, the objective of this 
study was to determine whether VEGF Trap 
(Regeneron Pharmaceuticals, Tarrytown, NY), 
a potent anti-VEGF angiogenesis inhibitor 
that traps circulating VEGF in the blood-
stream and in the extracellular space, would 
enhance radiation therapy in the human U87 
glioblastoma (GBM) tumor model. Because 
GBM tumors are among the most radiore-
sistant and vascular of neoplasms and are 
known to secrete high levels of VEGF25, U87 
GBM was deemed an appropriate model to 
assess the effects of VEGF Trap and radiation. 
It was hypothesized that inhibition of VEGF 
signaling by VEGF Trap would improve the 
human U87 glioblastoma model response 
to radiotherapy.
The administration of decoy soluble VEGF 
receptors has been found to be a very effective 
way to block the VEGF signaling pathway26–29. 
VEGF Trap is a unique human fusion protein 
comprising portions of human VEGF recep-
VEGF Trap In Combination With 
Radiotherapy Improves Tumor
Control In U87 Glioblastoma
Purpose 
To determine the effect of vascular endothelial growth factor VEGF Trap (Regeneron 
Pharmaceuticals, Tarrytown, NY), a humanized soluble vascular endothelial growth factor 
(VEGF) receptor protein, and radiation (RT) on tumor growth in U87 glioblastoma xenografts 
in nude mice.
Methods and Materials
U87 cell suspensions were implanted subcutaneously into hind limbs of nude mice. VEGF Trap 
(2.5–25 mg/kg) was administered every 3 days for 3 weeks alone or in combination with a single 
dose of 10 Gy or fractionated RT (3 x 5 Gy). In addition, three scheduling protocols for VEGF 
Trap plus fractionated RT were examined.
Results
Improved tumor control was seen when RT (either single dose or fractionated doses) was 
combined with the lowest dose of VEGF Trap (2.5 mg/kg). Scheduling did not significantly 
affect the efficacy of combined therapy. Although high-dose VEGF Trap (10 mg/kg or 25 mg/kg) 
significantly reduced tumor growth over that of RT alone, there was no additional benefit to 
combining high-dose VEGF Trap with RT. 
Conclusions 
Vascular endothelial growth factor Trap plus radiation is clearly better than radiation alone 
in a U87 subcutaneous xenograft model. Although high doses of VEGF Trap alone are highly 
efficacious, it is unclear whether such high doses can be used clinically without incurring normal 
tissue toxicities. Thus, information on lower doses of VEGF Trap and ionizing radiation is of 
clinical relevance. © 2007 Elsevier Inc. 
Key Words: Vascular endothelial growth factor Trap, Radiotherapy, Anti-angiogenic, 
U87 glioblastoma.
Introduction
Radiation (RT) therapy is an important treatment modality for many cancers; however, its therapeutic 
success is impeded by dose-limiting normal tissue toxicities and the development of radioresistance. 
Recent studies emphasize the importance of the tumor microvascular response in addition to the 
tumor cell response in determining tumor radioresistance1, 2. Ionizing radiation can directly induce 
endothelial cell apoptosis1, 3, which can inhibit tumor growth and lead to radiosensitization. However, 
in opposition to endothelial cell damage, radiation also induces signal transduction cascades, which 
contribute to radiation resistance through upregulation of proliferative, survival, and angiogenic 
pathways4. In particular, radiation induces vascular cytokines, such as vascular endothelial growth 
factor (VEGF)5, 6, one of the most potent endothelial cell survival factors7, which functions as a 
powerful antiapoptotic factor for endothelial cells in new blood vessels8, 9. Radiation-induced VEGF 
results in tumor radioresistance through vascular radioprotection2, 10.
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tor 1 (VEGFR1) and human VEGF receptor 2 (VEGFR2) extracellular 
domains fused to the constant region (Fc) of human IgG121. VEGF Trap 
has greater affinity for the VEGF ligand than anti-VEGF monoclonal 
antibodies (mab) do (dissociation constant <1 pMol/L for VEGF Trap 
vs. 0.1–10 nMol/L for mab)30. VEGF Trap has been shown to inhibit 
neoangiogenesis and tumor growth in tumor xenografts and metastases, 
as well as reduce the formation of malignant ascites14, 21, 31.
Methods and Materials
Analysis of VEGF levels in U87 tumor cells in culture 
U87 glioblastoma cells (American Type Culture Collection) were 
maintained in alpha MEM (Sigma-Aldrich, St. Louis, MO) with 10% 
fetal bovine serum (Atlanta Biologicals, Norcross, GA). U87 cells were 
irradiated at doses between 2 and 20 Gy in the presence or absence of 
40 nM VEGF Trap and incubated for 48 h. Using a commercially avail-
able human VEGF immunoassay kit (R&D Systems, Minneapolis, MN), 
VEGF was assayed from culture supernatants.
Animal and tumor model
U87 cell suspensions (5 x 105 cells in 100 μL phosphate buffered saline) 
were implanted subcutaneouly (SC) into the right hind limbs of athymic 
NCR NUM mice (Taconic Farms, Hudson, NY). A SC xenograft model 
was chosen to facilitate radiation dosing and ease of tumor measure-
ments in the more than 200 mice measured in this study. Mice were not 
pretreated before tumor implantation. U87 tumors were allowed to grow 
for approximately 14 to 18 days until reaching an approximate diameter 
of 4 to 5 mm before treatment.
Drug and irradiation treatment
In an initial pilot study, VEGF Trap was administered at two doses, a high 
dose (25 mg/kg) or low dose (2.5 mg/kg), every 3 days, up to 3 weeks, 
with or without a single dose of radiation (10 Gy) given on Day 0. VEGF 
Trap was administered every 3 days because it has a half-life of 72 h in 
mouse serum (drug pharmacokinetics communicated by Regeneron). 
Drug was administered 2 h before radiation. When fractionated radio-
therapy was used, VEGF Trap was combined at 2.5 mg/kg (low dose) 
or 10 mg/kg (intermediate dose) with fractionated radiotherapy (three 
fractions of 5 Gy each) on Days 0, 1, and 2. Scheduling of VEGF Trap was 
either 1 week before fractionated radiation and continuing for a period 
of 3 weeks, concurrent with radiation and continuing for a period of 3 
weeks, or 3 days postradiation treatment and continuing for a period 
of 3 weeks. Thus, the total number of drug doses was constant for each 
schedule (see Fig. 1 for dose and irradiation scheduling protocol).
Irradiation was performed on anesthetized mice using an X-ray machine 
(Gulmay Medical, Bethel, CT) operating at 250 kV, 10 mA, with a 2-mm 
aluminum filtration. The effective photon energy was ≈90 keV. Mice 
were anesthetized with a combination of ketamine and acepromazine at a 
concentration of 75 mg/kg and 0.35 mg/kg, respectively. Each mouse was 
confined in a lead casing with its tumor-bearing leg extended through 
an opening on the side to allow the tumor to be irradiated locally.
Radiation was administered as three daily fractions of 5 Gy each as 
described earlier.
Tumor size was measured 4 to 5 times per week after treatment by direct 
measurement with calipers and calculated by the formula [(smallest 
diameter (2) x widest diameter) / 2]. Tumors were not allowed to grow 
beyond 2,000 mm3 in accordance with Institutional Animal Care and Use 
Committee regulations.
Positron emission tomography imaging
The MOSAIC PET scanner (Philips Medical Systems, Brisbane, CA) 
was used for PET studies. Before imaging, mice were anesthetized with 
ketamine (75 mg/kg) and acepromazine (0.35 mg/kg) via a SC injection. 
Once anesthetized 0.3 to 0.5 μCi of 18-fluorodeoxyglucose (FDG) was 
administered intravenously. Sixty to seventy min were allowed for uptake 
of the tracer. Mice were placed in a 50-mL specimen tube to facilitate 
multimodality stereotactic positioning. The PET data were acquired in 
a single position for 15 min. Volumes of interest (VOIs) were defined by 
drawing multislice regions of interest (ROIs) on the PET images using 
50% of the full-width-at-half-maximum (FWHM) of the tumor to deter-
mine the tumor boundary. In the case of tumors with a core lacking FDG 
uptake, the tumor and core boundaries were defined by 50% FWHM of 
each wall adjacent to the core. Mice were divided into three groups (n 
= 3–6 animals per group): untreated; low-dose VEGF Trap–treated (2.5 
mg/kg), and highdose VEGF Trap–treated (10 mg/kg).
21147012
24147012 3
147012-7
211470
VEGF Trap + Single Dose RT  (10 Gy)
VEGF Trap + Fractionated RT  (3 x 5 Gy)
I
II
III
IV
Days
RT (1 day)
RT (3 days)
VEGF Trap (21 Days)
Figure 1. Scheduling protocols for vascular endothelial growth 
factor (VEGF) Trap administration in combination with radiation 
(RT). VEGF Trap was given at 2.5, 10, or 25 mg/kg every 3 days in 
four schedules: (I) VEGF Trap given on Day 0 concurrent with a 
single dose of RT (10 Gy) and continued up to 3 weeks; (II) VEGF 
Trap given on day –7 before RT (3 x 5 Gy) and continued for 3 
weeks; (III) VEGF Trap given on Day 0 concurrent with RT (3 x 5 
Gy) and continued up to 3 weeks; (IV) VEGF Trap given on Day 3 
post RT (3 x 5 Gy) and continued up to 3 weeks. All three protocols 
received the same number of drug doses. Day 0 was always the start 
of radiation.
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Immunohistochemistry
Platelet–endothelial cell adhesion molecule 1 (PECAM-1) immunos-
taining for microvessel density (MVD): control, radiation-treated, 
VEGF Trap–treated tumors, and VEGF Trap plus radiation–treated 
tumors were immunostained with a rat antimouse PECAM-1 mAb (BD 
Biosciences, Boston, MA) and a rabbit antirat biotinylated secondary 
antibody (Vector Labs, Burlingame, CA). Enhanced horseradish per-
oxidase–conjugated streptavidin and a substrate chromogen, AEC 
(3-amino-9-ethyl carbazole), were used to visualize the signal. (HIS-
TOSTAIN-PLUS kit, Invitrogen, Carlsbad, CA); slides were examined 
with a Nikon Eclipse E600 microscope to calculate MVD, the area 
occupied by the PECAM-1-positive microvessels, and total tissue area 
per section were quantified using National Institute of Health Image J 
software. Microvessel density was expressed as percent area of blood 
vessels stained per tissue section. Areas of necrosis were excluded 
from calculations. Four or five high-power fields were identified on 
each section with three to four sections per tumor and two tumors
per endpoint.
Statistical analysis of tumor growth
Tumor size measurements over time were obtained from the following 
groups: control; radiation alone; VEGF Trap, low dose (2.5 mg/kg), inter-
mediate dose (10 mg/kg), or high dose (25 mg/kg); and the correspond-
ing two radiation plus VEGF Trap combinations (n = 10–14 animals per 
group). Tumor growth over the entire study follow-up period was mod-
eled via mixed-effects linear regression. This approach fits a “random” 
growth curve to each animal’s data and then statistically “averages” these 
curves within each treatment group to estimate an overall “fixed effect” 
for each group. It also properly handles unbalanced data (i.e., different 
number of measurements for different animals) and takes into account 
the correlation of each animal’s measurements over time. Because tumors 
typically grow exponentially, the base-10 logarithm of tumor volume was 
modeled as a function of time and treatment. The interpretation of the 
linear model for the log of tumor volume is in terms of geometric means 
and geometric mean ratios (while the usual interpretation of a regression 
model for an untransformed outcome is in terms of arithmetic means and 
mean differences). The fitted linear growth curves fitted the data well. In 
addition, an allowance was made for the variance of the random effects to 
differ across groups to account for the larger variability of measurements 
in certain treated groups. All statistical analyses were conducted in SAS 
8.2 (SAS Institute, Cary, NC, 1999–2001).
The mixed-effects regression has multiple advantages over analyses of 
tumor growth delay that typically compare groups with respect to the 
average time it takes tumors to reach some arbitrary size (e.g., 2,000 
mm3). First, mixed-effects regression yields more general parameters 
of interest, such as average daily tumor growth rate and doubling time.
Second, it can investigate (if necessary) treatment interactions and non-
linear patterns of tumor growth. Finally, it is more efficient because it 
used the repeated tumor size measurements obtained over the entire 
study period.
Results
Effect of VEGF Trap and radiation on VEGF secretion in U87 cells 
in culture
Levels of VEGF increased in U87 culture supernatants in a dose-depen-
dent manner following irradiation (Fig. 2). The addition of VEGF Trap 
(40 nM) reduced free VEGF in the supernatant to undetectable levels.
Effect of VEGF Trap and radiation on U87 tumor growth inhibition
The linear models for the log-transformed tumor growth fitted the data 
quite well in all groups. The raw data for all treatment groups with regres-
sion lines are plotted in Figs. 3 through 6 with corresponding Tables 1 
through 4. The average daily percent increase in tumor volume for the 
untreated control group was consistent across all protocols and ranged 
between 27% and 31%, corresponding to a tumor doubling time between 
2.5 and 3.0 days (Tables 1–4). Radiation alone (both single or fractionated 
doses) or VEGF Trap alone (all doses) significantly reduced the tumor 
growth rate compared with control (p < 0.001, Figs. 3–6, Tables 1–4). 
Results with VEGF Trap in combination with single dose or fractionated 
radiotherapy are now summarized.
Effect of VEGF Trap and single dose radiation (10 Gy) on U87 tumor 
growth inhibition 
Table 1 presents tumor growth data based on the mixed-effects linear 
regression analysis described in Methods and Materials, and Fig. 3 pres-
ents the original animal data. In this experiment, a low dose of VEGF 
Trap (2.5 mg/kg) initiated concurrently with a single dose of 10 Gy was 
compared with a 10x higher dose of VEGF Trap (25 mg/kg) plus 10 Gy. 
The six groups are compared in terms of average daily tumor growth 
and doubling time. It can be seen from Table 1 and Fig. 3 that both low-
dose and high-dose VEGF Trap were effective inhibitors of daily percent 
increase in tumor volume (%Δ = 15% and 5%, respectively, vs. 31% for 
controls, p = 0.001). Although low-dose VEGF Trap was not significantly 
better than 10-Gy treatment alone, the combination of low-dose VEGF 
Trap and 10 Gy slowed daily tumor growth (%Δ = 12% vs. 18% for 10 
Gy alone and 15% for low VEGF Trap alone). Thus, a less than additive 
enhancement in tumor control over either modality alone was observed. 
High-dose VEGF Trap, as a single treatment modality, was highly effec-
tive in slowing daily percent increase in tumor volume (5% vs. 18% for 
10 Gy). Its efficacy was not improved by the addition of 10 Gy. This study 
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Figure 2. Effect of vascular endothelial growth factor (VEGF) 
Trap and radiation on VEGF secretion in U87 cells in culture. U87 
cells were irradiated at doses between 2 and 20 Gy in the presence 
or absence of 40 nM VEGF Trap. Cell culture supernatants were 
assayed for VEGF secretion 48 h following treatment. VEGF secre-
tion was undetectable in presence of 40 nM VEGF Trap.
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Figure 3. Effect of vascular endothelial growth factor (VEGF) Trap combined with single-dose radiation (10 Gy) on tumor growth in U87GBM. 
Individual mouse data for six treatment groups (n = 10–12 animals per group). VEGF Trap was given at 2.5 or 25 mg/kg starting on Day 0, 
concurrent with radiation and continuing every 3 days for 3 weeks (see schedule I, Fig. 1).
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Figure 4. Effect of vascular endothelial growth factor (VEGF) Trap initiated before fractionated radiation (3 x 5 Gy) on tumor growth in U87 GBM. 
Individual mouse data for 6 treatment groups (n = 10–14 animals/group). VEGF Trap was given at 2.5 or 10 mg/kg starting on Day –7 and continuing 
every 3 days for 3 weeks (see schedule II, Fig. 2).
BODINEJOURNAL 17
Radiotherapy
-7 0 7 14 21 28 42
10000
1000
100
10
Days
Tu
m
or
 V
ol
um
e 
(m
m
3 )
35
Control
-7 0 7 14 21 28 42
10000
1000
100
10
Days
Tu
m
or
 V
ol
um
e 
(m
m
3 )
35
-7 0 7 14 21 28 42
10000
1000
100
10
Days
Tu
m
or
 V
ol
um
e 
(m
m
3 )
35
VEG Trap (25 mg/kg)
-7 0 7 14 21 28 42
10000
1000
100
10
Days
Tu
m
or
 V
ol
um
e 
(m
m
3 )
35
-7 0 7 14 21 28 42
10000
1000
100
10
Days
Tu
m
or
 V
ol
um
e 
(m
m
3 )
35 -7 0 7 14 21 28 42
10000
1000
100
10
Days
Tu
m
or
 V
ol
um
e 
(m
m
3 )
35
Control Radiation (3 x 5 Gy)
VEGF Trap (2.5 mg/kg) VEGF Trap (2.5 mg/kg) + Radiation (3 x 5 Gy)
VEGF Trap (10 mg/kg) VEGF Trap (10 mg/kg) + Radiation (3 x 5 Gy)
Figure 5. Effect of vascular endothelial growth factor (VEGF) Trap sequenced concurrent with fractionated radiation (3 x 5 Gy) on tumor Growth in 
U87 GBM. Individual mouse data for six treatment groups (n = 10–14 animals per group). VEGF Trap was given at 2.5 or 10 mg/kg starting on Day 0 
and continuing every 3 days for 3 weeks (see schedule III, Fig. 3).
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Figure 6. Effect of vascular endothelial growth factor (VEGF) Trap sequenced post–fractionated radiation (3 x 5 Gy) on tumor Growth in U87 GBM. 
Individual mouse data for six treatment groups (n = 10–14 animals/group). VEGF Trap was given at 2.5 or 10 mg/kg starting on Day 3 and continuing 
every 3 days for 3 weeks (see schedule IV, Fig. 4).
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Table 1. Effect of VEGF Trap combined with single-dose radiation: Summary of tumor growth (Schedule I)
Treatment  %Δ (95% CI)  T2x  p values
Control (human FC protein)  31.0  (27–35)  2.6
RT (10 Gy)  18.0  (15–21)  4.2  0.001 vs. control, 0.19 vs. VEGF Trap (low)
VEGF Trap (2.5 mg/kg) 15.0  (13–28)  4.9  0.001 vs. control, 0.19 vs. RT alone
VEGF Trap (25 mg/kg)  5.0  (2–7)  15.2  0.001 vs. control, 0.001 vs. RT alone, 0.001 vs. VEGF Trap (low)
VEGF Trap (2.5mg/kg) + RT  12.0  (9–14)  6.3  0.003 vs. RT, 0.06 vs. VEGF Trap (low)
VEGF Trap (25 mg/kg) + RT  5.0  (2–7)  15.5  0.001 vs. RT, 0.417 vs. VEGF Trap (high), 0.96 vs. VEGF Trap (low) + RT
Abbreviations: %Δ = daily% increase in tumor volume; CI = confidence interval; RT = radiation; VEGF = vascular endothelial growth factor; T2x = average doubling time for tumor volume (in days).
Table 2. VEGF Trap initiated before fractionated radiation: Summary of tumor growth (Schedule II)
Treatment  %Δ (95% CI)  T2x  p values
Control (human FC protein)  27.0  (23–31)  3.0
RT (3 x 5 Gy)  11.0  (8–15)  6.5  0.001 vs. control, 0.59 vs. VEGF Trap (low), 0.027 vs. VEGF Trap (high)
VEGF Trap 2.5 mg/kg)  12.0  (10-15)  5.9  0.001 vs. control, 0.59 vs. RT
VEGF Trap 10 mg/kg) 7.0  (4–9) 11 0.001 vs control, 0.027 vs. RT, 0.001 vs. VEGF Trap (low)
VEGF Trap (low) + RT  7.0  (4–9)  10.6  0.034 vs. RT, 0.004 vs. VEGF Trap (low)
VEGF Trap (high) + RT  5.0  (2–7)  15.3  0.002 vs. RT, 0.33 vs. VEGF Trap (high)
Abbreviations: %Δ = daily% increase in tumor volume; CI = confidence interval; RT = radiation; VEGF = vascular endothelial growth factor; T2x = average doubling time for tumor volume (in days).
suggests that low-dose VEGF Trap in combination with single-dose 
radiation has an enhanced effect on tumor cell kill. It was thought that 
this enhancement might be improved by varying dose and scheduling 
protocol. Additional studies were carried out in which low-dose VEGF 
Trap at 2.5 mg/kg was compared with an intermediate dose of 10 mg/kg 
(because VEGF Trap at 25 mg/kg appeared to have masked any addi-
tional benefit of radiation in enhancing tumor control) in combination 
with a more clinically relevant fractionated radiotherapy protocol. The 
results of these studies are reported in the following sections.
Effect of VEGF Trap and fractionated radiation on U87 tumor growth 
inhibition 
VEGF Trap given before fractionated radiation: in this protocol, VEGF 
Trap was administered 7 days before radiation. The analyses allowed for 
separate tumor growth rates in the first and second periods (preradiation: 
Days –7 to 0; postradiation: Days 0+) for the groups that received radia-
tion. The study’s main aim was to compare tumor growth rates across treat-
ment groups in the latter period, when all treatments had been applied. 
Table 2 summarizes the results of the tumor growth modeling analyses 
during this main study phase, and Fig. 4 presents the original animal data. 
The low-dose VEGF Trap group (2.5 mg/kg every third day, starting at 
Day –7) demonstrated a reduction in daily percent increase in tumor 
volume (12% vs. 27% for control; p = 0.001) that was similar to the first 
single-dose radiation study, whereas the high-dose VEGF Trap group (10 
mg/kg every third day, starting at Day –7) had an even stronger effect 
(7%) that, again, was similar in trend to the first study. In the radiation 
only group, tumor daily growth was slowed to 11% (p < 0.001 vs. control). 
Although low-dose VEGF Trap was comparable to radiation alone (p = 
0.59), the combination of low-dose VEGF Trap with radiation (7% average 
daily percent increase in tumor volume, Table 1) was significantly better 
than either radiation alone (p = 0.036) or low-dose VEGF Trap alone (p 
< 0.005). The combination of high-dose VEGF Trap with radiation (5% 
average percent daily increase in tumor volume) was also significantly
better than radiation alone (p = 0.002) but not significantly better than high 
dose VEGF Trap alone (p = 0.33).
VEGF Trap given concurrently with fractionated radiation: Table 3 
summarizes the results of the tumor growth modeling analyses based 
on original animal data shown in Fig. 5. High-dose VEGF Trap was 
significantly better than radiation in reducing daily percent increase in 
tumor volume (8.5% vs. 16.1% for radiation, p = 0.001). The combina-
tion of low-dose VEGF Trap with radiation (12% average daily increase 
in tumor volume) was significantly better than either radiation alone 
(p = 0.029) or low-dose VEGF Trap alone (p = 0.012). The combination 
of high-dose VEGF Trap (10 mg/kg) with radiation (7% average daily 
increase in tumor volume) was also significantly better than radiation 
alone (p = 0.001) but not high-dose VEGF Trap alone (p = 0.417).
VEGF Trap given postradiation: Table 4 summarizes the results of the 
tumor growth modeling analyses based on original animal data shown 
in Fig. 6. The results of this schedule followed the same pattern as seen 
in the previous two schedules with fractionated radiation as well as the 
first experiment with single-dose radiation. The benefit of combining 
VEGF Trap with radiation compared with single-modality treatments 
was once again seen with low-dose VEGF Trap plus radiation. High-dose 
VEGF Trap at 10 mg/kg plus radiation significantly reduced percent daily 
increase in tumor volume when compared with radiation alone but was 
not significantly different from VEGF Trap alone (p = 0.187).
In summary, improved tumor control was seen when radiation (either 
single dose or fractionated doses) were combined with the lowest dose 
of VEGF Trap (2.5 mg/kg) used in these studies. Scheduling did not sig-
nificantly affectthe efficacy of combined therapy. The relative benefits 
of combined low-dose VEGF Trap plus fractionated radiation relative 
to radiation as judged by percent reduction in average daily increase in 
tumor volume were 36% for VEGF Trap given before radiation, 27% for 
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Table 3. Trap sequenced concurrently with radiation: Summary of tumor growth (Schedule III)
Treatment  %Δ (95% CI)  T2x  p values
Control (human FC protein)  27.0  (24–30)  2.9
RT (3 x 5 Gy)  16.0  (13–19)  4.6  0.001 vs. control, 0.729 vs. VEGF Trap (low), 0.001 vs. VEGF Trap (high)
VEGF Trap (2.5 mg/kg)  17.0  (14–19)  4.5  0.001 vs. control, 0.729 vs. RT alone
VEGF Trap (10 mg/kg)  8.5  (6–11)  8.5  0.001 vs. control, 0.001 vs. RT alone, 0.001 vs. VEGT Trap (low)
VEGF Trap (low) + RT  12.0  (9–14)  6.3  0.020 vs. RT, 0.008 vs. VEGF Trap (low)
VEGF Trap (high) + RT  7.0  (5–9)  10.3  0.001 vs. RAD, 0.392 vs. VEGF Trap (high), 0.014 vs. VEGF Trap (low) + RT
Abbreviations: %Δ daily% increase in tumor volume; CI = confidence interval; RT = radiation; VEGF = vascular endothelial growth factor; T2x = average doubling time for tumor volume (in days).
Table 4. VEGF Trap sequenced post–fractionated radiation: Summary of tumor growth (Schedule IV)
Treatment  %Δ (95% CI)  T2x  p values
Control (human FC protein)  31.5  (28–35)  2.5
RT (3 x 5 Gy)  15.0  (13–17)  5.1  0.001 vs. control, 0.460 vs. VEGF Trap (low), 0.001 vs. VEGF Trap (high)
VEGF Trap (2.5 mg/kg)  16.0  (13–19)  4.7  0.001 vs. control, 0.460 vs. RT alone
VEGF Trap (10 mg/kg)  8.0  (5–10)  9.2  0.001 vs. control, 0.001 vs. RT alone, 0.001 vs. VEGT Trap (low)
VEGF Trap (low) + RT  10.0  (7–12)  7.4  0.011 vs. RT, 0.001 vs. VEGF Trap (low)
VEGF Trap (high) + RT  5.5  (3–8)  12.8  0.001 vs. RT, 0.187 vs. VEGF Trap (high), 0.013 vs. VEGF Trap (low) + RT
Abbreviations: %Δ daily% increase in tumor volume; CI = confidence interval; RT = radiation; VEGF = vascular endothelial growth factor; T2x = average doubling time for tumor volume (in days).
concurrent treatment, and 32% for drug given postradiation treatment. 
Although high-dose VEGF Trap (either 10 mg/kg or 25 mg/kg) signifi-
cantly reduced tumor growth over that of radiation alone, there was no 
added benefit to combining high dose VEGF Trap with radiation. 
Effect of VEGF Trap and radiation on microvessel density 
Immunoassaying for endothelial cells with PECAM-1 revealed an inhi-
bition of tumor angiogenesis 3 weeks after treatment with VEGF Trap 
or VEGF Trap and radiation. Tumor MVD was similar in the control 
and radiation-treated tumors. Tumor MVD in the VEGF Trap treated 
tumors was decreased to between 43% to 57% of control or radiation-
treated tumors (p = 0.06). Tumor MVD in VEGF and radiation-treated 
groups decreased to between 15% and 30% of control or radiation-
treated groups (p = 0.001) (Fig. 7). There was no significant difference 
in MVD between high-dose VEGF Trap–treated with radiation vs. high 
dose VEGF Trap alone (p = 0.29). However, there was a significant 
difference in MVD between low-dose VEGF Trap-treated with radiation 
and low-dose VEGF Trap alone (p = 0.01, Fig. 8).
18-fluorodeoxyglucose–PET imaging of VEGF Trap–treated tumors
Figure 9a illustrates a series of images from a representative, untreated 
mouse. Figure 9b represents a series of images from a representative 
mouse treated with VEGF Trap dosed at or 10 mg/kg every 3 days 
(starting at Day 0) for 3 weeks. Tumor volume (mm3) and days following 
start of treatment are indicated. Because of the difficulty in matching 
tumor volumes and time after treatment, the percent of metabolically 
inactive tumor volume (as measured by FDG uptake) was measured as 
a function of tumor volume and averaged over a range of tumor volumes 
between 900 and 1,600 mm3. The percent of metabolically inactive 
tumor was significantly less in untreated tumors (2.46% ± 0.18%) than 
in tumors treated with 10 mg/kg VEGF Trap (8.7 ± 1.26%, p = 0.01) but 
not significantly different from tumors treated with 2.5 mg/kg VEGF 
Trap (3.36 ± 0.36%, p = 0.13) .
Discussion
This work demonstrated that VEGF Trap alone is an effective dose-
dependent inhibitor of tumor growth in U87GBM. These findings 
agreed with previous studies of VEGF Trap in other preclinical animal 
models demonstrating efficacy in halting angiogenesis and shrinking 
tumors30. Because VEGF Trap was very potent by itself and could have 
potentially masked any additional benefits of radiation, both low-dose 
and high-dose scheduling of the drug were used with radiotherapy. 
In all scheduling protocols that were investigated, the combination of 
low-dose VEGF Trap with radiation was significantly better than either 
treatment modality alone. On the other hand, high-dose VEGF Trap 
was significantly better than radiation alone and therefore masked any 
additional benefit that may have resulted from combination therapy.
The benefit of combined treatment with low VEGF Trap and radiation 
relative to radiation alone was not influenced by scheduling protocol. 
This result was in contrast to earlier work demonstrating improved 
radiation response when a VEGFR2 blocker, DC101, was given 4 to 
6 days before radiotherapy32. This earlier work suggested that tumor 
vasculature normalization occurred during pretreatment with the 
VEGFR2 blocker, a process in which pruning of immature and inef-
ficient blood vessels occurs leading to improved tumor perfusion and 
oxygenation and improved radiation response. The current observations 
may reflect the absence of a normalization effect by VEGF Trap on U87 
GBM vasculature or a missed window of opportunity for normalization 
because of the particular protocols used in this work. Because it is not 
known how tumor oxygenation levels may have varied throughout the 
course of combined treatment with VEGF Trap and radiation, addi-
tional studies are warranted to resolve the issue of normalization.
The observation that scheduling did not have an impact on efficacy of 
combined treatment with VEGF Trap and radiation in this study is also 
in contrast to recent studies in which VEGF blockade was obtained either 
by a VEGF receptor2 tyrosine kinase inhibitor, ZD6474, or indirectly by 
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Radiotherapy
HIF-1 alpha blockade of VEGF secretion. In both these studies, optimal 
antitumor efficacy was obtained when VEGF blockers were sequenced 
following radiation2, 33. These studies suggested that prolonged suppres-
sion of radiation-induced angiogenesis account for enhanced efficacy 
of combined treatments with angiogenesis blockade and radiation. 
However, it is not clearly understood why there is a difference in the 
impact of scheduling among these agents.
This work is encouraging in that it demonstrates for the first time a 
benefit in combining VEGF Trap with ionizing radiation in a highly resis-
tant GBM tumor model. VEGF Trap is a unique human fusion protein 
with very potent binding affinity for VEGF A isoforms as well as placental 
growth factor (PIGF) and is currently in clinical trials. Its affinity for 
VEGF is potentially 100- to 1,000-fold higher than existing VEGF mono-
clonal antibodies such as bevacizumab34. This high-affinity blockade of 
VEGF differentiates VEGF Trap from other anti-VEGF strategies and 
therefore gives this drug the potential to enhance combination modality 
treatment with lower dosing.
Mechanisms of enhanced U87 tumor control by combined therapy with 
VEGF Trap and radiation most likely include inhibition of radiation-
induced angiogenesis by VEGF Trap sequestration of circulating VEGF 
in the bloodstream and in the extracellular tumor space resulting from 
radiation-induced secretion. Indeed, in this study, a radiation-dose-
dependent increase in VEGF secretion by U87 glioblastoma cells was 
observed and excess VEGF was bound in the presence of VEGF Trap. In 
addition, immunohistochemical findings indicated a reduction in MVD 
3 weeks following treatment with VEGF Trap and radiation. Inhibition 
of radiation-induced angiogenesis was also observed indirectly through 
FDG–PET imaging, which revealed an increase in metabolically inac-
tive tumor tissue after VEGF Trap treatment, possibly arising from the 
induction of tumor necrosis or apoptosis in the presence of angiogenesis 
inhibition. It is also of interest that in this study, a brief period of fraction-
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Figure 7. Effect of vascular endothelial growth factor (VEGF) Trap 
and radiation (RT) (Schedule II) on microvessel density (MVD). 
Tumor MVD in VEGF Trap–treated tumors was decreased to 
between 43% and 57% of control or RT-treated tumors (p = 0.06). 
Tumor MVD in VEGF Trap and RT-treated groups decreased to 
between 15% and 30% of control or RT-treated groups  (p = 0.001). 
There was no significant difference in MVD between VEGF Trap–
treated (high dose) + radiation vs. VEGF Trap (high dose) alone 
(p = 0.29). However, there was a significant difference in MVD 
between VEGF Trap (low dose) + radiation and VEGF Trap (low 
dose) alone (p = 0.01).
Control VEGFT L VEGFT H
Radiation VEGFT L + R VEGFT H + R
Figure 8.  Platelet– endothelial cell adhesion molecule 1 (PECAM-
1) staining in subcutaneous U87 glioblastoma xenografts treated 
with vascular endothelial growth factor (VEGF) Trap with and 
without radiation therapy (Schedule II). Lower microvessel density 
(MVD) and altered vessel morphology were observed in treated 
tumors. (VEGFT L = VEGF Trap low dose; VEGFT H = VEGF Trap 
high dose; R = radiation) Original magnification: X 100.
A
B
*Volume (mm3) / (days
post-treatment)
Figure 9. 18-fluorodeoxyglucose (FDG)–PET imaging of human 
U87 glioblastoma xenografts in nude mice. (a) A series of typical 
images from an untreated mouse. (b) A series of images from a 
mouse treated with vascular endothelial growth factor (VEGF) 
Trap dosed at 10 mg/kg every 3 days (starting at Day 0) for 3 weeks. 
Tumor volume (mm3) and days following start of treatment are 
indicated. Imaging was performed as described in Methods and 
Materials. The percent of metabolically inactive tumor (as measured 
by FDG uptake) was significantly less in untreated tumors than in 
tumors treated with 10 mg/kg VEGF Trap.
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ated radiotherapy with VEGF Trap resulted in tumor growth retardation 
but not remission. The lack of remission is probably related to continued 
production of VEGF after removal of drug and radiation and points to 
the need for chronic therapy with VEGF Trap, which is in agreement with 
what has been observed for the transient effects of other antiangiogenic 
agents on tumor control23, 35.
In conclusion, these studies demonstrate that the combination of low-
dose VEGF Trap and radiation is clearly better than radiation alone in 
a U87 subcutaneous xenograft model. Although high doses of VEGF 
Trap alone are highly efficacious, it is unclear whether such high doses 
can be used clinically without incurring normal tissue toxicities. Thus, 
information on lower doses of VEGF Trap and ionizing radiation are of
clinical relevance.
It is understood that the SC xenograft model used in this study has 
shortcomings in that ectopic tumors implanted SC in the hind limb of 
animals do not duplicate the vascular microenvironment of orthotopic 
brain implants36. However, the use of hind limb injection is the standard 
approach for xenograft studies with radiation. In addition, human xeno-
grafts in immunocompromised nude mice, whether they be ectopic or 
orthotopic, both have deficiencies in that they can only approximate the 
human patient situation and seldom reflect accurately the glioblastoma 
multiforme histopathology seen in patients. This study is encouraging in 
that it demonstrates for the first time a benefit in combining VEGF Trap 
with ionizing radiation and warrants further investigations both preclini-
cally and clinically.
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Abreviations: MO, antisense morpholino oligonucleotide; PFTα, pifithrin-α; 
Hpf, hours post fertilization; Kd, knock down; IR, ionizing radiation
Key Words: zebrafish, development, radiation effects, tumor suppressor 
protein p53, tumor suppressor protein p73, pifithrin-α
The p53 family of proteins contains two members that have been implicated in sensitization of cells 
and organisms to genotoxic stress, i.e., p53 itself and p73. In vitro, lack of either p53 or p73 can pro-
tect certain cell types in the adult organism against death upon exposure to DNA damaging agents. 
The present study was designed to assess the relative contribution of p53 to radiation resistance of 
an emerging vertebrate model organism, i.e., zebrafish embryos. Consistent with previous reports, 
suppressing p53 protein expression using antisense morpholino oligonucleotides (MOs) increased 
survival and reduced gross morphological alterations in zebrafish embryos exposed to ionizing 
radiation. By contrast, a pharmacological inhibitor of p53 function [Pifithrin-α (PFTα)] caused 
developmental abnormalities affecting the head, brain, eyes and kidney function and did not pro-
tect against lethal effects of ionizing radiation when administered at 3 hours post fertilization (hpf). 
The phenotypic abnormalities associated with PFTα treatment were similar to those caused by 
antisense MO knock down (kd) used to reduce p73 expression. PFTα also inhibited p73-dependent 
transcription of a reporter gene construct containing canonical p53-responsive promoter sequences. 
Notably, when administered at later stages of development (23 hpf), PFTα did not cause overt devel-
opmental defects but exerted radioprotective effects in zebrafish embryos. In summary, this study 
highlights off-target effects of the pharmacological p53 inhibitor PFTα related to inhibition of p73 
function and essential roles of p73 at early but not later stages of zebrafish development.
Introduction
The genotoxic stress response is one of the most widely studied phenomena in biology and the 
efforts of many groups have provided a detailed understanding of the molecular determinants of 
this homeostatic mechanism (reviewed in refs. 1–3). Yet, the current understanding of the effects of 
genotoxic stress on whole organisms is curtailed by the fact that many of the mechanistic insights are 
based on experiments with cultured cells. These shortcomings are compounded by pitfalls associated 
with the preferential use of immortalized or transformed cells.4 In recognition of these problems, 
many groups have resorted to studying the DNA damage response in experimental animals, particu-
larly genetically engineered mice. These efforts have contributed considerably to the understanding 
of molecular determinants of the in vivo genotoxic stress response including Ku,5,6 DNA-PK,7 DNA 
ligase IV,8 ATM,9 ATR,10 Chk111 and Chk2.12 In addition, these studies confirmed a central role of the 
tumor suppressor p53 in the genotoxic stress response (reviewed in refs. 13 and 14). 
The present study was undertaken to explore molecular determinants of the genotoxic stress 
response in an emerging animal model system, i.e., zebrafish embryos. Zebrafish represents a 
vertebrate species with many similarities to mammals. Yet, they breed prolifically and are ame-
nable to large-scale phenotypic screening facilitated by the fact that they are transparent during 
organogenesis. Importantly, ‘knockdown’ strategies using antisense MOs have been developed in 
this species to investigate protein function in 
the in vivo context. Zebrafish are attractive 
not only to model human diseases but also as 
tools in drug discovery.15 We have previously 
reported that zebrafish embryos provide a 
rapid, facile system to identify pharmacologi-
cal modifiers of the radiation response.16 Here, 
we extend these studies to assess the contribu-
tion of endogenous modifiers of the radiation 
response to radiation-induced morbidity and 
mortality by focusing on pharmacological and 
genetic inhibition of p53 function.
Results and Discussion
Time- and dose-dependent effects of ioniz-
ing radiation on zebrafish embryo survival.
Previously, we observed that radiation sen-
sitivity of zebrafish embryos was different at
distinct developmental stages and progres-
sively decreased between 2 to 8 hours post
fertilization (hpf ).16 Here, we extend this earlier 
study by assessing embryo survival after expo-
sure to increasing radiation doses up to 72 h 
after radiation. These experiments confirmed 
progressive radioresistance at successive stages 
of development (not shown). To determine 
the consequences of inhibiting translation of 
specific gene products by antisense MO kd for 
radiation resistance of the developing embryo 
we performed all subsequent experiments in 
embryos which were irradiated at 24 hpf. This 
was based on the consideration that, at this time 
point, target protein expression is sufficiently 
suppressed by antisense MO kd and remains 
low for extended time periods up to 4 days post 
fertilization (dpf ).17 Dose-dependent survival 
upon radiation exposure at 24 hpf revealed 
100% lethality scored at 6–7 dpf (40 Gy) with 
an LD50 of 20 Gy.18 To monitor the effects of 
p53 expression on radiation sensitivity as it 
relates to both, mortality and tissue-specific 
effects, we thus performed experiments at 20 
or 40 Gy.
Reduced p53 expression is associated 
with radioprotection of zebrafish embryos. 
Zebrafish embryos harboring homozygous 
missense p53 mutations exhibit increased 
resistance to the deleterious effects of ionizing 
radiation.19 We determined whether suppressing 
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p53 expression by antisense MOs20 similarly induced a radioresistant 
phenotype. We observed that p53-targeted MO kd markedly improved 
survival of zebrafish embryos irradiated with 20 Gy at 24 hpf (Fig. 1A) 
whereas coinjection of capped p53 mRNA restored radiation sensitivity 
(Fig. 1B). Similarly, p53-targeted MO kd markedly reduced the incidence 
and severity of radiation-induced morphological defects, notably defects 
in midline development that manifest as dorsal curvature of the body 
axis (Fig. S1). These results were similar to results by Duffy and Wick-
strom published during preparation of this manuscript.21 In addition, 
p53-targeted MO kd markedly reduced the extent of radiation-induced 
apoptosis as determined by acridine orange staining (Fig. 1C). 
Effects of the pharmacological p53 inhibitor PFTα on development 
and radiation sensitivity of zebrafish embryos. PFTα was originally 
identified as an inhibitor of p53-dependent transcription22 and it reduced 
the sensitivity of mice to the deleterious effects of ionizing radiation.23 
Based on these previous studies we tested whether PFTα also protected 
zebrafish embryos against radiation-associated toxicity (Fig. 2A). Unex-
pectedly, when added to zebrafish embryos at 3 hpf (sphere stage), PFTα 
(2 μM) caused malformations affecting the head region and led to the 
development of massive edema affecting the whole body of treated fish 
at later stages of development (Fig. 2B and Table 1). Furthermore, it has 
been described earlier that PFTα treatment also reduces overall survival 
of zebrafish embryos.21 These results together raised the question whether 
PFTα exerted effects on molecular targets other than p53, which confound 
potential radioprotective properties of PFTα in the zebrafish embryo.
PFTα treatment mimics morphological effects associated with knock-
down of p73 expression in zebrafish embryos. P73 is a likely candidate 
for off-target effects of PFTα because p73 binds to and transactivates 
p53 responsive promoters.24 Thus, we determined whether suppression 
of p73 expression by antisense MO kd caused developmental defects 
similar to those observed in PFTα treated embryos. A previous report 
showed that targeting p73 adversely affected development of the head 
region, i.e., the olfactory system, the telencephalon and the pharyngeal 
arches of zebrafish embryos.25 In addition, p73 is expressed at high levels 
in the developing kidneys.26 We observed that p73-targeted antisense 
MO-mediated kd induced head region abnormalities (Fig. 3A) and led 
to liquid accumulation affecting the whole body of treated fish (Fig. 4 
and Table 2). These changes were very similar to the morphological 
alterations observed in PFTα-treated fish (Fig. 2B). Furthermore, alcian 
blue staining revealed severe disturbances of branchial arch development 
associated with either PFTα treatment or p73-targeted antisense MO kd 
(Fig. 3B). These defects were, at least partially, reversed by coinjection 
of G-capped p73 mRNA and not observed in embryos injected with p73 
mismatched antisense MO.
Impaired kidney function in zebrafish treated with PFTα and p73 
morpholinos. This is the first report of edema formation upon treatment 
of developing embryos with p73-targeted antisense MO kd. We hypoth-
esized that this phenotype was due to impaired renal clearance consistent 
with high-level expression of p73 in the developing kidneys.26 To address 
this issue we used a renal function assay, which measures retention of a 
fluorescent dextran within 24 h after injection into the cardiac venous-
sinus.27 As compared to control fish receiving mismatch antisense MO, 
the p73-targeted antisense MO kd caused markedly reduced clearance 
of this contrast agent (Fig. 5). In contrast, control p53-specific antisense 
MO kd did not affect dextran retention. Importantly, PFTα treatment not 
only led to liquid accumulation in fish embryos in a manner similar to 
p73-targeted antisense MO kd but it also increased dextran retention in 
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Figure 1. Antisense morpholino oligonucleotides (MOs) targeted to 
p53 increase embryo survival and reduce ionizing radiation-induced 
apoptosis evident in the head and trunk regions. (A) Embryo survival. 
Triplicate dishes of 60 embryos each were scored for live embryos daily 
after 20 Gy IR administered at 24 hpf. Necrotic dissolution or absent 
heartbeat were considered criteria for embryo death. (B) Restoration of 
IR sensitivity by restoring p53 expression using G-capped zebrafish p53 
mRNA. Triplicate dishes of 60 embryos each were scored as described 
above at 6 dpf (5 days post IR). Asterix (*) p53kd vs p53kd-p53 mRNA; p 
< 0.05; t-test, one-tailed). (C) Attenuation of IR-induced apoptosis by p53 
kd as assessed by quantification of acridine orange (AO) staining at 30 
hpf. Sixty embryos per condition (Control, phenol red control; p53 mm, 
mismatch antisense MO; p53 kd, p53 antisense MO; p53 kd-p53mRNA, 
rescue coinjection with p53 antisense MO and p53 G-capped mRNA) 
were pooled and stained with AO as described in Materials and Methods. 
Pooled embryos were transferred to 95% ethanol for 15 minutes to 
extract the AO for fluorescence determination. Triplicate measurements 
for each condition were performed on a FL600 microplate fluorescence 
reader (Bio-Tek) and normalized to control background fluorescence 
and reported as relative fluorescence units (RFU).
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a similar fashion. In these experiments, kidney function was tested at 3 
dpf and prior to the development of edema to avoid confounding effects 
of the liquid accumulation on embryonal kidney function.
An alternative explanation for the profound edema in zebrafish embryos 
following IR exposure is that this effect was caused by reduced cardiac 
function.28 To investigate this possibility, we performed time-lapse 
microscopy of cardiac contractility in control and irradiated fish embryos. 
Quantitative analysis of the images revealed only marginal effects of 
either PFTα treatment or p73-specific antisense MO kd on heart rate 
and blood flow (not shown). Collectively, these results suggest that the 
edema observed in PFTα and p73 antisense MO kd zebrafish embryos is 
due primarily to compromised renal function.
PFTα inhibits p73-dependent transactivation of a p53-respon-
sive promoter construct. The striking similarities in developmental 
abnormalities caused by either PFTα treatment of suppression of p73 
expression raised the question whether PFTα targeted not only p53-
dependent but also p73-dependent transcription. Using a p53 responsive 
reporter gene construct and zebrafish p53 and p73 expression plasmids 
cotransfected into Saos-2 cells we observed that PFTα not only inhibited 
p53-dependent transcription but also p73-dependent transcription in a 
dose-dependent manner (Fig. 6).
It should be noted that administration of PFTα shortly before radiation 
(i.e., at 23 hpf ) did not cause developmental abnormalities either of the 
craniofacial region or systemic edema and provided a measure of protec-
tion against radiation similar to that observed in p53 antisense MO kd 
fish (Fig. S1). This result indicates that p73 serves essential functions 
during the first 24 h of zebrafish development but is less relevant at later 
developmental stages and, presumably, in the adult organism. This cir-
cumstance also explains why inhibition of p73 function by PFTα has not 
been obvious in previous in vitro or in vivo studies in adult mice.
In summary, this report demonstrates the utility of the zebrafish 
model system in characterizing drug effects and highlights previously 
unrecognized effects of the p53 inhibitor PFTα related to inhibition 
of p73 function. Lack of either p53 or p73 function is associated with 
chemoresistance of transformed cells.29 Furthermore, p73 is induced 
after DNA damage by the checkpoint kinases Chk1 and Chk2.30 Based 
on these results, p73 has been considered as the “assistant” guardian 
of the genome that acts in concert with p53 to limit propagation of 
cells with damaged DNA.31 Since we observed that PFTα inhibits not 
only p53-dependent but also p73-dependent transcription the overall 
radioprotective effect of PFTα as observed in mice may, thus, be due to 
inhibition of p53 and p73 function. Indeed, short-term pharmacological 
inhibition of both, p53 and p73 may be superior to inhibition of p53 
alone to protect normal adult cells and tissues against deleterious effects 
of radiation.
Materials and Methods
Embryo harvesting and maintenance. Zebrafish husbandry, embryo 
collection, dechorionation and embryo maintenance were performed 
according to accepted standard operating procedures32 and with approval 
by the Institutional Animal Care and Use Committee at Thomas Jeffer-
son University. Zebrafish were maintained in the Zebrafish Core Facility 
of the Kimmel Cancer Center at Thomas Jefferson University at 28.5°C 
on a 14-h light/10-h dark cycle.
Zebrafish morphology by visual analysis. For visual analysis, zebrafish 
embryos were anesthetized with 0.003% tricaine, placed on 3% meth-
ylcellulose on a glass depression slide and analyzed using an Olympus 
BX51 microscope (Olympus, Melville, NY) at 4x magnification. Images 
were recorded using a SPOT camera and SPOT Advanced software 
(SPOT Diagnostic Instruments, Sterling Heights, MI).
Targeted knock down of gene expression. Antisense MO sequences 
targeting p53, p73 and controls (5 base mismatches; p53 mm, p73 mm) 
were as described.20,25 For microinjection, a 0.5 mM oligonucleotide solu-
tion was prepared in 10x phosphate-buffered saline solution, diluted 9:1 
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Figure 2. PFT-α (2 μM) administered to zebrafish embryos at 3 hpf does not protect against the lethal effects of IR and is associated with developmental 
abnormalities. (A) Embryo survival scored as described in Figure 1A. (B) Embryo morphology in the different experimental conditions as indicated. 
Representative embryos were digitally photographed at 4x magnification and processed using NIH ImageJ software.
Table 1. 
Incidence of whole body edema caused by PFTα treatment
 Normal Edema  Total  Edema (%)
Control  77  0  77  0
PFTα (2μM)  18  29  47  62
Triplicate dishes (30 embryos each per condition) of live embryos at 7 dpf were scored for edema as shown 
in Figure 2B and results expressed as percent edema.
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(v:v) with Phenol Red dye, and ~1 nL injected into 1–4 cell embryos 
using a nitrogen gas pressure injector (Harvard Apparatus, Cambridge, 
MA). To account for non-specific effects of MO oligonucleotides, rescue 
experiments were carried out by coinjection of MOs with G-capped 
mRNA of the respective target gene. To this end, triplicate dishes of 60 
embryos were injected with 4.5–7.5 pg of mRNA generated by clon-
ing the zebrafish p53 cDNA or p73 cDNA into the pCS2+ vector and
producing mRNA with the mMessage-mMachine SP6 kit (Ambion, 
Austin, TX).
Radiation exposure and PFTα protection. Triplicate dishes (60 embryos 
each) were irradiated at 24 hpf (20 Gy) using 250 kVp X-rays (PanTak, East 
Haven, CT) at 50 cm source-to-skin with a 2-mm aluminum filter. Dosi-
metric calibration was performed before each experiment using a thimble 
ionization chamber (Victoreen; Elimpex-Medizintechnik, Moedling, Aus-
tria) with daily temperature and pressure correction. Pifithrin-α (EMD 
Biosciences, San Diego, CA) was solubilized in DMSO and diluted with 
embryo media. PFTα was applied 30 minutes prior to IR.
Kidney function assay. A 1% solution of rhodamine-labeled dextran (10 
kDa; Molecular Probes) in PBS was injected (3 dpf ) using glass micropi-
pets into the cardiac venous sinus of embryos immobilized in 3% methyl 
cellulose. Prior to injection, embryos were anesthetized using a 0.003% 
tricaine solution in egg water.33 After injection, the embryos were washed 
in egg water for 10 minutes and placed back into 3% methylcellulose 
on a glass depression slide. Fluorescence was quantitated using ImageJ 
software (NIH, USA). The analysis was repeated at 24 h after dextran 
injection. Percent dextran retention at 24 h was calculated using the for-
mula: (intensity 24 h/intensity 0 h) X 100.
Figure 3. PFT-α treatment (2 μM at 3 hpf) affects cranio-facial develop-
ment reducing brain, eye and auditory organ size. (A) Embryo head 
morphology at 6 dpf. Representative embryos were digitally photo-
graphed at 10x magnification and processed using NIH ImageJ software 
(a) snout, (b) eyes, (c) auditory cup. (B) Alcian blue staining (described 
in Materials and Methods) of cartilage shows markedly abnormal 
cranio-facial development associated with PFT-α treatment and with 
p73 antisense MO kd.
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Figure 4. Phenotypic abnormalities associated with PFT-α treatment 
are similar to those caused by MO-mediated p73 kd. PFT-α was admin-
istered at 3 hpf. Embryo morphology and rescue by G-capped mRNA. 
Representative embryos were digitally photographed at 4x magnification 
and processed using NIH ImageJ software.
Table 2. Incidence of whole body edema caused by p73kd
 Normal Edema  Total  Edema (%)
Control  219  1  220  0
p73 MO  121  126  247  51
p73 mm  64  4  68  6
p73 MO/mRNA  151  37  188  20
Live embryos at 7 dpf were scored for edema as described in Figure 4 and results expressed as 
percent edema.
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Alcian blue staining. Alcian blue staining was performed according to 
Neuhauss et al.,34 with the following modifications. Embryos (4 dpf ) 
were fixed overnight in Davidson’s Solution (Electron Microscopy Sci-
ences, Hatfield, PA) and rinsed 3x for 10 min in PBS and transferred to 
neutral buffered formalin for 2 days at 4°C. The embryos were then trans-
ferred into distilled water and stored at 4°C. For Alcian blue staining, the 
samples were washed in PBT (0.1% Tween-20 in PBS) and transferred 
into 30% H2O2 (Sigma, St. Louis, MO) and bleached for 4–5 hours or 
until eyes became translucent. After bleaching, the embryos were rinsed 
in PBS for 15 min and transferred to filtered Alcian Blue solution (1% 
conc HCl, 70% Ethanol, 0.1% Tween-20) and stained overnight. The 
stain was cleared with acidic ethanol (5% conc HCl, 70% ethanol).
Acridine orange staining. Zebrafish embryos were dechorionated and 
placed in 50 μg/ml of acridine orange (Sigma) in fish water. After 30 min 
of staining, embryos were washed 3x for 10 min in PBS. Pooled embryos 
were transferred to 95% ethanol for 15 minutes to extract the AO for 
fluorescence determination. Triplicate measurements for each condition 
were performed on a FL600 microplate fluorescence reader (Bio-Tek) 
and normalized to control background fluorescence and reported as rela-
tive fluorescence units (RFU).
In vitro reporter gene assays. Saos-2 cells (ATCC Rockville, MD) were 
cultured in DMEM supplemented with 10% fetal calf serum. Cells were 
cultured to 60–70% confluence and transferred to 48-well plates at a 
density of 2.6 x 104 cells/well. Cells were transfected with three plasmids 
Figure 5. Reduced kidney function by either PFT-α treatment or p73 kd as determined by increased fluorescent dextran retention. (A) Rhodamine labeled 
dextran staining is described in Materials and Methods. Representative images are shown at 0 and 24 h. (B) Quantification of dextran label retention at 24 h 
after dye injection. Three embryos per condition were quantified for dye retention using NIH imageJ software.
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Figure 6. PFT-α inhibits p73-dependent transcription of a reporter gene construct. Triplicate wells (48-well plate) were transfected with pCMV- gal and 
p53 pr-RLuc plasmids together with either a pCMV-zp53 (A) or a pCMV-zp73 plasmid. (B) Renilla luciferase activity was assayed 48 h post transfection 
and normalized to -gal activity as described in the Materials and Methods. Cells were treated with PFT-α 15 minutes before transfection. Asterix (*) p < 0.5 
(tukey test); **p < 0.01(tukey test).
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using Fugene (Roche). The p53 reporter plasmid was constructed by 
inserting the synthetic p53-responsive promoter containing 14 tandem 
p53 enhancer elements and a TATA-box (Pathdetect p53-cis reporter, 
Stratagene) into the pRLnull plasmid (Promega) to drive the Renilla 
luciferase gene (p53 pr-RLuc). For normalization, a B-galactosidase 
reporter plasmid was used (pCMV-Bgal;35). Renilla luciferase activity was 
measured 48 hrs after transfection using the Dual-Luciferase Reporter 
Assay System (Promega, Madison, WI) and B-gal activity was measured 
using the Beta-Glo Reporter Assay System (Promega, Madison, WI) 
according to the manufacturer’s specifications. Cells were treated 
with PFTα 15 minutes before transfection. Chemiluminescence was 
measured using a Veritas Microplate luminometer (Turner Biosystems,
Sunnyvale, CA).
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Increasing Tumor Volume Is Predictive of Poor Overall 
and Progression-Free Survival: Secondary Analysis of 
the Radiation Therapy Oncology Group 93-11 Phase I-II 
Radiation Dose-Escalation Study In Patients With 
Inoperable Non-Small-Cell Lung Cancer
Purpose
Patients with non–small-cell lung cancer (NSCLC) in the Radiation Therapy Oncology Group 
(RTOG) 93-11 trial received radiation doses of 70.9, 77.4, 83.8, or 90.3 Gy. The locoregional control 
and survival rates were similar among the various dose levels.We investigated the effect of the gross 
tumor volume (GTV) on the outcome.
Methods and Materials
The GTV was defined as the sum of the volumes of the primary tumor and involved lymph nodes. 
The tumor response, median survival time (MST), and progression-free survival (PFS) were analyzed 
separately for smaller (≤45 cm3) vs. larger (>45 cm3) tumors.
Results
The distribution of the GTV was as follows: ≤45 cm3 in 79 (49%) and >45 cm3 in 82 (51%) of 161 
patients. The median GTV was 47.3 cm3. N0 status and female gender were associated with better 
tumor responses. Patients with smaller (≤45 cm3) tumors achieved a longer MST and better PFS 
than did patients with larger (>45 cm3) tumors (29.7 vs. 13.3 months, p < 0.0001; and 15.8 vs. 8.3 
months, p < 0.0001, respectively). Increasing the radiation dose had no effect on the MST or PFS. 
On multivariate analysis, only a smaller GTV was a significant prognostic factor for improved MST 
and PFS (hazard ratio [HR], 2.12, p = 0.0002; and HR, 2.0, p = 0.0002, respectively). The GTV as a 
continuous variable was also significantly associated with the MST and PFS (HR, 1.59, p < 0.0001; 
and HR, 1.39, p < 0.0001, respectively).
Conclusions
Radiation dose escalation up to 90.3 Gy did not result in improved MST or PFS. The tumor responses 
were greater in node-negative patients and women. An increasing GTV was strongly associated 
with decreased MST and PFS. Future radiotherapy trials patients might need to use stratification by 
tumor volume. ©2008 Elsevier Inc.
Key Words: Tumor volume, Lung cancer, Radiotherapy dose escalation.
Introduction 
The current American Joint Committee on Cancer staging system for the primary tumor in lung 
cancer is based mostly on the tumor extent and involvement of the neighboring structures (e.g., 
pleura, chest wall, mediastinum, bone, esophagus, and proximal airways) rather than on tumor 
size or volume. A notable exception is Stage T1, in which a tumor surrounded completely by lung 
parenchyma cannot exceed 3 cm in the largest dimension. However, a Stage T2 tumor can measure 
1.5 cm or 8 cm, as long as it invades the visceral pleura only, with sparing of the other structures. 
Evidence has been accumulating1–11 that an 
increasing tumor volume has a significant 
effect on patient outcome, possibly even 
overriding the T stage assignment. Other factors 
influencing the American Joint Committee on 
Cancer stage assignment are nodal involvement 
and the presence of distant metastases.
In a recently published Radiation Therapy 
Oncology Group (RTOG) Phase I-II study12 
of radiation dose escalation for patients 
with inoperable non–small cell-lung cancer 
(NSCLC), the observed locoregional control 
rates and survival rates were similar between 
treatment groups, receiving escalated radiation 
doses (from 70.9 Gy to 90.3 Gy, depending on 
the volume of lung receiving ≥20 Gy [V20]).
A reasonable initial hypothesis would be, 
however, to expect that smaller tumors should 
demonstrate improved local control with greater 
radiation doses compared with larger tumors.
To investigate this hypothesis, we undertook a 
retrospective analysis of data from the RTOG 
93-11 clinical trial in an attempt to demonstrate 
any benefit of radiation dose escalation for 
patients with smaller tumors and to determine 
any relationship between the initial tumor 
volume and patient outcome.
Methods And Materials
Patient population
The RTOG 93-11 study was a Phase I-II 
radiation dose escalation trial for patients with 
inoperable Stage I-III NSCLC treated with 
three-dimensional (3D) radiotherapy alone, 
without concurrent chemotherapy, although 
induction chemotherapy was allowed. 
The primary objective of the study was to 
determine the treatment-related morbidity and 
to determine the maximal tolerated radiation 
dose. The secondary objectives were to 
determine the local control and overall survival 
(OS) rates. The patient population consisted of 
subjects with NSCLC (inoperable Stage I, II, 
and IIIA and Stage IIIB; supraclavicular nodes 
involvement was not allowed; Table 1). Patients 
were treated according to the volumetric 
treatment planning computed tomography 
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findings and the gross tumor volume (GTV) included the primary 
tumor and any enlarged regional lymph nodes (>1 cm) with a minimal 
3D margin of 1 cm. Noninvolved nodal areas were not irradiated, and 
no special effort was made to account for the respiratory motion, apart 
for assessing motion with fluoroscopy. Patients were placed into dose-
escalation groups according to the V20 value in their radiotherapy (RT) 
plan, predicting the likelihood of treatment-related pneumonitis13. 
Patients with a V20 of <25% were assigned to Group 1 and received 
an escalated dose to 70.9, 77.4, 83.8, or 90.3 Gy. Patients with a V20 of 
26–35% were assigned to Group 2 and received an escalated dose to 70.9, 
77.4, or 83.8 Gy. Patients with a V20 of >35% were assigned to Group 3 
and received an escalating dose to 64.5, 70.9, or 77.4 Gy. All fraction sizes 
were 2.15 Gy. The study accrued patients only to Groups 1 and 2. Group 
3 enrollment was stopped because of poor accrual.
Evaluation of local control, OS, and progression-free survival
A chest X-ray was obtained 4 weeks after RT completion. Computed 
tomography scans of the chest were obtained at 6 and 12 months and 
repeated yearly thereafter. Local control (complete response [CR] or 
partial response [PR] vs. stable or progressive disease) was reported by 
the enrolling institutions. No central review of the follow-up computed 
tomography scans was performed. OS and progression-free survival 
(PFS) were reported as measured from the date of registration in
the study.
Statistical analysis
The GTV was defined as the sum of the volumes of the primary tumor 
and involved lymph nodes. In the 3D plans, the primary tumor volume 
and the involved nodal volume were outlined as one structure; no data 
are available in the RTOG electronic database to allow for separation of 
those two volumes. Therefore, in an attempt to at least partially correct 
this deficiency, nodal status (N0 vs. N1 or N2 or N3) was analyzed as 
one of the variables. This allowed for the separation of the effect of 
the tumor GTV vs. nodal GTV (at least for Stage I, or N0, patients). 
OS was defined as death from any cause; an event for PFS was local or 
regional progression, distant metastases, or death from any cause. For 
the purpose of this investigation, tumor response, OS, and PFS were 
analyzed separately for the smaller tumors (≤45 cm3) vs. larger tumors 
(>45 cm3), first among all patients and, later, within each radiation dose 
level. GTV was also analyzed as a continuous variable. The association 
of response (CR/PR vs. stable/progressive disease) and the GTV 
categorized by cutpoint was tested by Fisher’s exact test. OS and PFS were 
estimated by the Kaplan-Meier method and tested using the log–rank 
test statistic. Univariate and multivariate analyses of OS and PFS with the 
GTV and other prognostic factors (age [<60 vs. ≥60], gender, Karnofsky 
performance status [90–100 vs. 70–80], histologic type [nonsquamous 
vs. squamous], stage [I-II vs. IIIA-IIIB], previous chemotherapy [yes vs. 
no], and maximal radiation dose to the lung) were done using the Cox 
proportional hazards model. Multivariate modeling used the stepwise 
selection method. When analyzed as a continuous variable, GTV was 
transformed using a log10 transformation to ensure normality. Patients 
with unknown tumor volumes were excluded from this analysis.
Results
Patient characteristics
A total of 176 patients were included in the original report of the study12. 
Of the 176 patients, 161 had available data on GTV and tumor response 
and were the subject of this secondary analysis. The patient characteristics 
are presented in Table 1. Overall, most patients were older (>60 years) 
with a Karnofsky performance status between 70 and 80. The patients in 
this analysis were approximately equally split between men and women 
and those in Group 1 were more likely to have node-negative disease 
than were those in Group 2. The distribution of the American Joint 
Committee on Cancer stage was Stage I in 67, Stage II in 12, and Stage 
III in 48 patients in Group 1 and Stage I in 10, Stage II in 3, and Stage III 
in 35 patients in Group 2.
Tumor response, OS, and PFS
The GTV was ≤45 cm3 in 79 (49%) and >45 cm3, 82 (51%) of 161 patients 
(median, 47.3; range, 1.9–1,039.9 cm3); 14 patients had an unknown 
GTV. The tumor response rate (CR/PR) was better for smaller tumors 
(≤45 cm3) than for larger tumors (>45 cm3; 87% vs. 76%, respectively), 
as was stable/progressive disease (13% vs. 24%, respectively; p = 
0.0691, Fisher’s exact test). Results using a cutoff point of 30 cm3 did 
not better distinguish between those patients with a tumor response 
and those with stable or progressive disease than using a cutoff point 
of 45 cm3 (p = 0.0642). A cutoff point of 60 cm3 did not discriminate 
between the two groups (p = 0.4139). When the GTV was analyzed as a 
continuous variable, on univariate analysis, it was borderline statistically 
significantly associated with tumor response (p = 0.0551); however, on 
multivariate analysis, N stage (N0 vs. N1-N3) and female gender were 
the only significant variables (p = 0.025 and p = 0.02, respectively). This 
can be explained by the greater rate of responses (70%) in patients with 
N0 disease vs. N1-N3 (30%).
Patients with smaller tumors (≤45 cm3) achieved a longer median survival 
than did patients with larger tumors (>45 cm3; 29.7 vs. 13.3 months, p 
< 0.0001; Fig. 1), as well as better median PFS (15.8 vs. 8.3 months; p < 
0.0001; Fig. 2).
When a different GTV was chosen as a cutoff point (30 cm3 or 60 cm3), 
patients with smaller tumors (≤30 cm3 or ≤60 cm3) still achieved better 
OS (32.9 vs. 14.6 months for 30 cm3, p = 0.0002; and 26.8 vs. 13.3 months 
for 60 cm3, p = 0.0006), as well as better PFS (15.5 vs. 9.0 months for 30 
cm3, p = 0.0031; and 14.7 vs. 8.7 months for 60 cm3, p = 0.0023).
Table 1. Patient characteristics
Characteristic  Group 1 (n = 127)  Group 2 (n = 48)
Age (y)
  <60   18 (14)   5 (10)
 ≥60 109 (86)  43 (90)
Gender (n)
 Male  72 (57)  22 (46)
 Female  55 (43)  26 (54)
KPS (n) 
 70–80  85 (67)  30 (63)
 90–100  42 (28)  18 (37)
Histologic type (n)
 Squamous cell carcinoma 51 (40)  21 (44)
 Adenocarcinoma  42 (33)  17 (35)
 Other  34 (21)  10 (21)
N stage (n)
 N0  83 (65)  17 (35)
 N1  10 (8)    6 (13)
 N2  32 (25)  22 (46)
 N3    2 (1)    3 (6)
Abbreviation: KPS = Karnofsky performance status.
Data in parentheses are percentages.
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When the effect of GTV was analyzed on univariate analysis, a smaller 
GTV was associated with improved OS, with significant hazard ratios 
(HRs) for cutoff points of 30 cm3 (HR, 2.15; p = 0.0002); 45 cm3 (HR, 
2.14; p < 0.0001); and 60 cm3 (HR, 1.91; p = 0.0008), as well as for GTV 
analyzed as a continuous variable (HR, 1.59; p < 0.0001). The other 
variables associated with improved OS on univariate analysis were female 
gender (p = 0.0407) and nodal status (p = 0.067, borderline significance). 
The same factors were significant for PFS on univariate analysis (data 
not shown).
On multivariate analysis of the factors associated with improved OS 
and PFS, only a smaller tumor volume was significantly prognostic 
for both endpoints (HR, 2.12; p = 0.0002; and HR, 2.0; p = 0.0002, 
respectively) when GTV was analyzed as a continuous variable. Age, 
gender, performance status, histologic type, N stage (N0 vs. N1-N3), 
previous chemotherapy, and maximal radiation dose were not significant 
(Tables 2 and 3). The other GTV cutoff points (≤30 cm3, ≤45 cm3, and ≤60 
cm3) retained their statistically significant association with improved OS 
and PFS on multivariate analysis and again were the only factors in the 
multivariate models using a stepwise selection method.
Effect of radiation dose escalation on tumor response, OS, and PFS by 
tumor volume
The primary research hypothesis of this study was that higher radiation 
doses would lead to increased efficacy in smaller tumors. Table 4 shows 
the frequencies and percentages of patients with a CR/PR and stable or 
progressive disease for each radiation dose and GTV combination using 
the 45 cm3 cutoff point. No evidence was found in these data that the CR/
PR rates increased as the radiation dose increases for the two categories 
of GTV (p = 0.2213). Increasing the radiation dose had no effect on OS 
or PFS (data not shown for PFS) when examined separately for smaller 
vs. larger tumors when the 45-cm3 GTV cutoff point was used (Table 
5). The results for the 30-cm3 and 60-cm3 cutoff points were similar 
(data not shown). The consistently statistically significant increase in the 
relative risk of death for all doses to a GTV >45 cm3 can be attributed to 
the strong effect of a larger GTV on OS rather than the radiation dose. 
However, the analysis was not powered to detect a dose–tumor volume 
interaction, and it could not be ruled out on the basis of this analysis.
Discussion
The aim of RTOG 93-11 was to determine the dose-limiting toxicity of 
3D RT. The radiation dose was safely escalated to 83.8 Gy for patients 
with V20 <25% and to 77.4 Gy for patients with a V20 of 25–36%. The 
90.3-Gy dose level was too toxic. The observed locoregional control was 
similar among the study arms, without evidence that the higher doses 
eliminated or at least lowered the recurrence rates.
Our initial hypothesis was that patients with volumetrically smaller 
tumors would have improved survival with radiation dose escalation but 
not patients with larger tumors. However, we were not able to demonstrate 
that in this secondary analysis of the RTOG 93-11 trial, at least not with 
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Figure 1. Five-year overall survival rate for patients with gross tumor 
volume ≤45 cm3 (solid curve) vs. those with gross tumor volume >45 
cm3 (dotted curve).
Figure 2. Five-year progression-free survival rate for patients with gross 
tumor volume ≤45 cm3 (solid curve) vs. those with gross tumor volume 
>45 cm3 (dotted curve).
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Table 2. Multivariate analysis of overall survival for 
different gross tumor volumes used as cutoff point and 
as continuous variable
 Model* Comparison  Hazard ratio  95% CI  p†
GTV (cm3)  <30 vs. ≥30  2.18  1.43–3.32  0.0003
GTV (cm3)  ≤45 vs. >45  2.12  1.43–3.13  0.0002
GTV (cm3)  ≤60 vs. >60  1.87  1.27–2.75  0.0015
GTV‡  Continuous  1.59  1.33–1.91  <0.0001
Abbreviation: CI = confidence interval; GTV = gross tumor volume; KPS = Karnofsky performance status.
*Following covariates did not meet entry criteria for any multivariate model: age (<60 vs. ≥60 y), gender 
(female vs. male), KPS (90–100 vs. 70–80), histologic type (nonsquamous vs. squamous), N stage (N0 vs. 
N1-N3), previous chemotherapy (no vs. yes), or maximal dose to lung (continuous).
†Chi-square test using Cox proportional hazards model; stepwise selection, with entry level of 0.05 and exit 
level of 0.10.
‡GTV transformed using log10 to ensure normalcy.
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the small patient numbers that were available at each radiation dose 
level tested. It could be that doses >83.8 Gy in standard fractions are 
necessary to eliminate local failure. Additionally, the protracted overall 
treatment time of 7–9 weeks might have facilitated tumor repopulation 
and therefore attenuated any radiation dose response. Finally, the 
PTV margins were tight (1–1.5 cm around the GTV), which might 
have increased the likelihood for a marginal miss in mobile tumors, 
obliterating any potential benefit of dose escalation.
Such a benefit has been suggested in the Memorial Sloan-Kettering 
Cancer Center experience4, with the observation of improved local 
control and survival in Stage III NSCLC patients with large (>100 cm3) 
tumors treated with radiation doses >64 Gy compared with those who 
received lower radiation doses.
A significant interaction between radiation dose and tumor size was 
shown in the University of Michigan retrospective analysis5 of 114 
patients with medically inoperable Stage I and II NSCLC treated with 3D 
conformal RT in a dose-escalation study. Patients treated to a biologically 
equivalent dose of ≤79.2 Gy lived longer if their tumors did not exceed 
51.8 cm3 in volume. However, patients treated to a biologically equivalent 
dose of >79.2 Gy had the same overall survival, irrespective of tumor 
volume. With all the limitations of the retrospective study, a hypothesis 
has been raised that radiation dose escalation can result in improved 
outcome in NSCLC, at least in node-negative, early-stage tumors.
In the reports of highly hypofractionated (‘‘radioablative’’) RT using 
precise localization techniques to account for tumor motion, very high 
local control rates have been achieved in medically inoperable patients 
with Stage I NSCLC receiving 60 Gy in three fractions of 20 Gy each10 
or other hypofractionated regimens11. Such doses have not yet been 
tested in Stage III NSCLC and might be too dangerous for large and
central tumors.
We found that the increasing tumor volume, defined as the sum of the 
primary tumor volume and the volume of the involved lymph nodes, 
was associated with a greater risk of local failure, with significantly better 
control achieved with tumors <45 cm3 than with the larger tumors. The 
45-cm3 volume corresponds roughly to a spherical tumor diameter of
4.4 cm. It must be remembered that the ‘‘tumor volume’’ in our analysis 
denoted a sum of the volume of the primary tumor and the involved 
lymph nodes, if any. However, in the multivariate analysis of the tumor 
volume studied as a continuous variable, it was only the earlier nodal 
stage and female gender, not the tumor volume, that was associated with 
better local control. In reality, those two variables (volume and nodal 
stage) overlap to a large degree, because Stage I NSCLC is defined as a 
node-negative tumor measuring ≤3 cm in the largest dimension. Separate 
values for the primary GTV and the nodal GTV were not available in the 
RTOG 93-11 study; therefore, we were unable to isolate their respective 
influences on outcomes.
Because a rigorous evaluation of locoregional control was not performed 
in the RTOG 93-11 trial, local control was not assessed in an actuarial 
fashion and the radiographic responses might not reflect the true biologic 
tumor elimination; using survival as an endpoint is a more objective 
measure of the relevance of tumor volume. A strong association of 
increasing tumor volume with worsened survival and PFS was observed 
in our analysis, overriding other known prognostic factors for survival, 
such as lower disease stage.
Such an association has been previously reported1–9. In 207 patients with 
inoperable NSCLC (Stage I-III) treated at the Washington University 
with 3D-conformal thoracic RT1, overall survival, cause-specific 
survival, and local tumor control were highly correlated with the GTV, 
and the GTV (and pathologic findings) were predictive for survival on 
multivariate analysis, but overall stage and nodal stage were not. Those 
patients with tumor volumes not exceeding 33 cm3 appeared to have the 
best outcome.
Local response was evaluated volumetrically on 107 followup thoracic 
computed tomography scans of 22 patients (19 with Stage III NSCLC) 
Table 3. Multivariate analysis of progression-free survival for 
different gross tumor volumes used as cutoff point and as
continuous variable
 Model* Comparison  Hazard ratio  95% CI  p†
GTV (cm3)  <30 vs. ≥30  1.74  1.20–2.53  0.0039
GTV (cm3)  ≤45 vs. >45  2.00  1.40–2.86  0.0002
GTV (cm3)  ≤60 vs. >60  1.65  1.16–2.36  0.0056
GTV‡  Continuous  1.39  1.18–1.64  <0.0001
Abbreviations as in Table 2.
*Following covariates did not meet entry criteria for any multivariate model: age (<60 vs. ≥60 y), gender 
(female vs. male), KPS (90–100 vs. 70–80), histologic type (nonsquamous vs. squamous), N stage (N0 vs. 
N1-N3), previous chemotherapy (no vs. yes), or maximal dose to lung (continuous).
†Chi-square test using Cox proportional hazards model; stepwise selection, with entry level of 0.05 and exit 
level of 0.10.
‡GTV was transformed using log10 to ensure normality.
Table 4. Frequency of tumor response subdivided by radiation
dose level and gross tumor volume cutpoint of 45 cm3
Incidence (n)
GTV ≤45 cm3  CR/PR  SD/PD  p*
Dose 70.9 Gy  13 (93) 1 (7)  0.2736
Dose 77.4 Gy  14 (82) 3 (18)
Dose 83.8 Gy  15 (88)  2 (12)
Dose 90.3 Gy  23 (88)  3 (12)
Dose 70.9 Gy  21 (70)  9 (3)
Dose 77.4 Gy  19 (68)  9 (32)
Dose 83.8 Gy  12 (92)  1 (8)
Dose 90.3 Gy  8 (89)  1 (11)
Abbreviation: CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease; 
GTV = gross tumor volume.
Data in parentheses are percentages. 
*Fisher’s exact test.
Table 5. Multivariate analysis of overall survival subdivided by 
radiation dose level and gross tumor volume cutpoint of 45 cm3
 Model* n  Hazard ratio  95% CI  p†
GTV ≤45 cm3, dose 83.8 Gy  17  1.60  0.65–3.93  0.3058
GTV ≤45 cm3, dose 77.4 Gy  17  1.10  0.43–2.82  0.8432
GTV ≤45 cm3, dose 70.9 Gy  14  1.57  0.63–3.91  0.3301
GTV >45 cm3, dose 90.3 Gy  9  4.20  1.52–11.64 0.0058
GTV >45 cm3, dose 83.8 Gy  13  3.83  1.53–9.60  0.0041
GTV >45 cm3, dose 77.4 Gy  28  2.41  1.06–5.48  0.0361
GTV >45 cm3, dose 70.9 Gy  30  2.61  1.17–5.84  0.0193
Abbreviations as in Table 4.
Reference level: GTV ≤45 cm3, dose 90.3 Gy.
*Chi-square test using Cox proportional hazards model.
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treated with definitive thoracic RT2. A volumeof ≤63cm3 and a diameter of 
≤4 cm were significantly associated with improved local control compared 
with larger volumes or diameters. In a large series from Wuerzburg6, 784 
scans of 136 patients were evaluated volumetrically, and a cutoffpoint of 
100 cm3 for tumor volume was a discriminating factor for local control, 
but not survival. In that study, the primary tumor volume and nodal 
volume were measured separately. The total tumor volume (tumor 
plus nodes), as well as primary tumor volume alone, was a significant 
prognostic factor for survival in a Japanese group experience7.
Because most of the studies cited in our report included a significant 
proportion of patients with nodal involvement (N1-N3), the relative 
prognostic value of the ‘‘T’’ tumor volume vs. the ‘‘N’’ nodal volume 
needs to be elucidated. One would expect that worse survival and possibly 
lower local control would be associated with an increasing nodal volume 
rather than the primary tumor volume. However, contradictory data 
have been published on this issue. On univariate analysis of the factors 
associated with overall survival and failure-free survival in a Phase I-
II radiation dose-escalation trial3, only the increasing GTV (defined as 
tumor plus nodes), but not the nodal stage or the overall stage, were 
predictive. Similarly, in the Japanese experience7 of 71 patients with 
Stage III NSCLC, on univariate analysis, the total tumor volume and the 
primary tumor volume were significant and the nodal volume was not. 
On multivariate analysis, the total tumor volume and primary tumor 
volume were both significant prognostic factors.
Investigators from Shanghai Medical University8 created a prognostic 
index model predicting for local control in patients with NSCLC treated 
with RT. Patients with a smaller tumor volume (primary plus nodal), 
earlier clinical stage, and treated with higher total irradiation dose with 
a shortened overall treatment time had better local control.
In a Classification and Regression Tree analysis of the Thomas Jefferson 
University’s 107 patients with Stage III NSCLC (9), an aggregate nodal 
volume >12.5 cm3 (sum of volumes of the abnormal hilar and mediastinal 
lymph nodes), as well as a central tumor location, but not the primary 
tumor volume, were associated with a greater risk of nodal recurrence 
and shorter median survival time than a nodal volume of ≤12.5 cm3 
(MST 13.9 months vs. 17.1 months, respectively). We are not aware of 
other reports that have focused on the prognostic value of the involved 
nodal volume.
Conclusions
Our study is one of several publications demonstrating the importance 
of tumor volume in patients receiving thoracic RT for NSCLC. It is not 
fully clear whether patients with smaller tumors have better outcomes 
simply because of the lower number of clonogenic cells or whether 
smaller tumors are inherently more biologically favorable; however, the 
tumor volume may need to be considered in the staging system for lung 
cancer, once user-friendly volume assessment becomes commonplace in 
diagnostic studies.
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Factors Associated with Severe Late 
Toxicity After Concurrent Chemoradiation 
for Locally Advanced Head and Neck 
Cancer: An RTOG Analysis
Purpose
Concurrent chemoradiotherapy (CCRT) for squamous cell carcinoma of the head and neck 
(SCCHN) increases both local tumor control and toxicity. This study evaluates clinical factors that 
are associated with and might predict severe late toxicity after CCRT.
Methods
Patients were analyzed from a subset of three previously reported RTOG trials of concurrent 
chemoradiotherapy for locally advanced SCCHN (RTOG 91-11; 97-03; and 99-14). Severe late 
toxicity was defined in this secondary analysis as chronic Grade 3-4 pharyngeal/laryngeal toxicity 
(RTOG/EORTC late toxicity scoring system) and/or requirement for a feeding tube ≥2 years after 
registration and/or potential treatment-related death (e.g. pneumonia) within 3 years. Case-control 
analysis was performed, with a multivariable logistic regression model that included pre-treatment 
and treatment potential factors.
Results
A total of 230 patients were evaluable for this analysis, 99 cases (patients with severe late toxicities) 
and 131 controls; thus 43% of evaluable patients had a severe late toxicity. On multivariable analysis, 
significant variables correlated with the development of severe late toxicity were older age (odds ratio 
1.05 per year; p = 0.001); advanced T-stage (odds ratio 3.07; p=0.0036); larynx/hypopharynx primary 
site (odds ratio 4.17; p=0.0041); and neck dissection after chemo-RT (odds ratio 2.39; p=0.018).  
Conclusions
Severe late toxicity following CCRT is common. Older age, advanced T-stage, and larynx/
hypopharynx primary site were strong independent risk factors. Neck dissection after CCRT was 
associated with an increased risk of these complications.
Background/Introduction 
Concurrent chemoradiotherapy (CCRT) is a standard treatment for patients with locally advanced 
squamous cell carcinoma of the head and neck (SCCHN) treated non-surgically.  Meta-analyses 
show an improved 5-year survival by approximately 8% when CCRT is compared to radiotherapy 
alone1, 2. The advantage of this approach with respect to disease free survival and local-regional 
control is greater than 8%3-6, 7-10.
While there are undisputed advantages to CCRT for local-regional control, it increases toxicity 
when compared to radiotherapy alone11. Many studies have focused on acute toxicity, particularly 
mucositis, as summarized in a meta-analysis 
by Trotti et al.12. Comprehensive data on late 
toxicity from randomized trials of RT +/- 
chemotherapy, however, are sparse. Late toxicity 
may include long-term severe dysphagia and 
its related effects, including dependence upon 
a feeding tube, and have a profound effect on 
quality of life. The increased incidence of these 
serious, potentially permanent effects after 
CCRT is concerning, leading some to question 
as to whether chemoradiotherapy is truly a 
major improvement in the therapeutic ratio 
over radiotherapy alone.13
Starting approximately 15 years ago, the RTOG 
conducted a series of prospective clinical trials 
using CCRT for locally advanced SCCHN. 
General data on efficacy and early and subacute 
toxicity have been reported14-16. It is likely, 
however, that each individual study is 
underpowered for a thorough analysis of late 
effects, given sample size and patient attrition 
due to mortality and other causes. Consequently, 
we performed a secondary analysis of severe late 
toxicities from these several trials, specifically 
focusing on late toxicities and mortality related 
to pharyngolaryngeal dysfunction.  An analysis 
of potential factors associated with severe late 
toxicities was undertaken.
Materials/Methods
As noted above, the three prospective trials 
analyzed for this paper have been previ-
ously reported. All three studies required an 
acceptable performance status (60-100% by 
Karnofsky scale); non-metastatic stage III/IV 
SCCHN; and good hematologic, renal, hepatic 
and cardiovascular function.
Briefly, the three studies are:
RTOG 91-1114: A phase III trial of larynx-
preserving radiotherapy or chemoradiotherapy 
for selected Stage III/IV larynx cancer. For
this analysis, only the concurrent chemo-
radiotherapy arm was studied; this treatment 
in this arm consisted of 70 Gy in convention-
ally fractionated radiotherapy (XRT) – 2 Gy 
once daily – plus three cycles of high dose
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RTOG Analysis
cisplatin (100 mg/m2, Weeks 1, 4, and 7). There were 172 patients in 
this arm from RTOG 91-11; 88 patients were evaluable for this analysis 
of late toxicity. 
RTOG 97-0317:  A Phase IIR trial of several novel regimens of concur-
rent chemoradiotherapy for stage III/IV head and neck cancer (excluding 
patients who were eligibile for RTOG 91-11). This study included three 
arms. Arms 1 and 3 utilized conventionally fractionated XRT as per 91-
11. Arm 1 chemotherapy was infusional 5-FU and cisplatin, both given 
daily during the last two weeks of XRT. Arm 3 chemotherapy was once 
weekly cisplatin (20 mg/m2/week) and paclitaxel (30 mg/m2/week). 
Arm 2 chemoradiotherapy was modeled upon the prospective phase 
II trials performed by the University of Chicago. In Arm 2, although 
the total XRT dose remained 70 Gy in 2 Gy fractions, it was delivered 
over 13 weeks (week-on, week-off technique); chemotherapy in Arm 2 
consisted of concurrent infusional 5-FU and hydroxyurea. There were 
231 patients in RTOG 97-03; 102 patients were evaluable for this analysis 
of late toxicity.
RTOG 99-1416: A Phase II trial of accelerated radiotherapy with 
concurrent chemotherapy for stage III/IV head and neck cancer. This 
single arm phase II study consisted of accelerated concomitant boost 
radiotherapy to 72 Gy over 6 weeks (as per the concomitant boost arm of 
RTOG 90-03), with two cycles of high dose cisplatin (100 mg/m2 weeks 1 
and 4). There were 76 patients in RTOG 99-14; 40 patients were evaluable 
for this analysis of late toxicity.
All of these studies used conventional radiotherapy techniques, mostly 
2-dimensional planning and delivery. No patient received intensity 
modulated radiation therapy (IMRT). For this report, a severe late 
toxicity was defined as any or all of the following events:
•  Grade 3 or greater toxicity (RTOG/EORTC Late Toxicity Criteria) 
present > 180 days after the start of XRT and clearly related to 
dysfunction of the larynx and/or pharynx (e.g. dysphagia)
•  Requirement for a feeding tube/gastrostomy 2 years or longer after the 
start of XRT. 
• Death without cancer progression and from an uncertain cause in 
which laryngeal dysfunction is suspected to be a contributing factor 
(e.g. pneumonia) ≤ 3 years from the date of randomization. Patients 
who died of unknown causes were included in this category. Review 
of these deaths was performed by one of the study authors (MM) in 
a manner blinded to any of the patient’s clinical pre-treatment and/or 
treatment related characteristics. 
Patients who suffered one or more qualifying severe late toxicity events 
were only considered to be one “case.”
Patients with severe laryngopharynx dysfunction due to cancer, prior to 
the start of treatment, were excluded because of the potential confounding 
nature of tumor destruction of critical normal tissues (See Table 1). In 
RTOG 91-11, the determination of severe pre-treatment laryngopharynx 
dysfunction was based on patients’ on-study data collection form, which 
scored airway obstruction and dysphagia on a 4-point scale (none, mild, 
moderate, severe/life-threatening); patients with severe/life-threatening 
airway obstruction and/or dysphagia based on this form were excluded. 
In RTOG 91-11, data on pre-treatment use of feeding tubes were not 
collected. In RTOG 97-03 and RTOG 99-14, pre-treatment feeding tube 
data were collected, and this was used as the primary means of defining 
patients with pre-treatment severe laryngopharynx dysfunction.  
Patients with missing/inevaluable data or early death from acute toxicity 
were also excluded.
Statistical Analysis
Frequency tables with counts and percentages were used to describe 
pretreatment and treatment characteristics for each group.  Univariate 
and multivariable logistic regression models were used to identify 
associations of pretreatment and treatment-related factors with severe 
late toxicity.  All models were stratified by the 5 treatment arms described 
above.  The following factors were studied: age (continuous variable); 
gender; race (non-black vs. black); KPS (60-80 vs. 90-100); hemoglobin 
(continuous variable); weight loss pre-treatment (continuous variable); 
T-stage (T1/2 vs. T3/4); N Stage (Nx/0/1 vs. N2 vs. N3); Tumor site 
(oral cavity/oropharynx vs. larynx/hypopharynx); radiotherapy dose 
received as assessed by late effects BED model (total RT dose multiplied 
by (1+ [dose/fraction size] ÷ 3): continuous variable); chemotherapy 
dose received (<85% of planned dose vs. > 85% of planned dose); and 
post-RT neck dissection (yes vs. no).  Variables’ levels were grouped in 
order to avoid small cell counts.  A stepwise selection procedure was 
used to build the multivariable logistic regression model using the above 
pretreatment/treatment variables.  Entry criterion was set at p < 0.05. 
The odds ratios (OR) for each variable in the final model along with 
their 95% confidence intervals and p-values are reported.  The odds 
ratios estimate how much more (less) likely it is to be in the case group 
versus the control group among patients with the specific variable level’s 
characteristic compared to those patients in the reference level (RL), after 
stratifying for treatment arm. The cumulative incidence method was 
used to estimate time to severe late toxicity and levels for pre-treatment/
treatment-related variables were compared using the Gray’s test 18, 19.
Table 1. Summary of Patients Excluded from this Analysis
RTOG 91-11 
(Original 
N=172)
RTOG 97-03 
(Original 
N=231)
RTOG 99-14 
(Original 
N=76)
Total
(Original 
N=479)
Reason for Exclusion 
Severe Pre-treatment  15 — — 15
Airway Obstruction
Severe Pre-treatment  5 — — 5
Dysphagia
Pre-treatment Feeding  — 62 18 80
Tube Dependence
Total Excluded due to  20 62 18 100
Severe pre-treatment 
laryngopharynx 
dysfunction
Death from Acute  2 3 1 6
toxicity
Tumor Recurrence/ 52 62 16 130
death < 3 yrs followup.
Missing Data 10 2 1 13
Grand Total Excluded 84 129 36 249
Total Analyzable  88 102 40 230
for this study
Abbreviations as in Table 4.
Reference level: GTV ≤45 cm3, dose 90.3 Gy.
*Chi-square test using Cox proportional hazards model.
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Results
The original, potential patient population from these three studies was 
479. However, there were 130 patients excluded because of local-regional 
failure or death due to cancer, 100 patients excluded because of severe 
pre-treatment laryngopharynx dysfunction due to tumor, 13 patients 
excluded because of missing data, and 6 patients excluded because of 
early death due to acute toxicity (see Table 1);. Thus, the overall evaluable 
sample size for this report was 230 patients.  The median followup for the 
patient population is 2.96 years.
Of these 230 patients, 99 patients (cases) had severe late toxicity and 
131 patients (controls) did not have severe late toxicity. This results in 
a crude rate of late toxicity of 43%. It should be noted that if the entire 
population of patients (N=479) from all three studies are analyzed (as is 
often performed for studies of late effects) the crude rate would appear 
to be 21%., considerably lower than the data reported here. An actuarial 
plot of “Time to Severe Late Toxicity” for all 230 evaluable patients is 
shown in Figure 1.
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Figure 1. Time to  Severe Late Toxicity Events – All Evaluable Patients.
Table 2. Summary of patients with severe late toxicities (cases) 
and patients without severe late toxicities (controls)
Case Group
(n=99)
Control Group 
(n=131)
Age
 Median 60 56
 Range 33-78 26-78
 Age ≤  70 85  (86%) 118  (90%)
 Age >  70 14  (14%) 13  (10%)
Gender
 Male 78  (79%) 99  (76%)
. Female 21  (21%) 32  (24%)
Race
 Non-Black 90  (91%) 120  (92%)
 Black 9  (  9%) 11  (  8%)
KPS  
 60-80 24  (24%) 20  (15%)
 90-100 75  (76%) 111  (85%)
Hemoglobin  
 Median 14.3 14.2
 Range 7.1-18.2 9.9-18.2
 Hgb  ≤  13.5 gm/dl 28  (28%) 43  (33%)
 Hgb  >  13.5 gm/dl 71  (72%) 88  (67%)
Weight Loss in Previous 6 months (kg)  
 Mean 3.9 2.8
 ≤  5 kg 78  (79%) 112  (86%)
 >  5 kg 21  (21%) 19  (14%)
T Stage  
 T1/T2  18  (18%) 39  (30%)
 T3/T4 81  (82%) 92  (70%)
N Stage  
 NX/N0/N1 47  (47%) 63  (48%)
 N2 42  (42%) 58  (44%)
 N3 10  (10%) 10  (  8%)
Tumor Site  
 Oral cavity/oropharynx 42  (42%) 71  (54%)
  Oral Cavity 7    (7%) 5    (4%)
  Oropharynx 35  (35%) 66  (50%)
Larynx/hypopharynx  57  (58%) 60  (46%)
  Larynx 41  (41%) 51  (39%)
  Hypopharynx 16  (16%) 9     (7%)
Radiotherapy Dose-Intensity 
delivered (BED)  
 Mean 115 Gy 116 Gy
 Median 117 Gy 117 Gy
 Range 67-117 Gy 111-126 Gy
Neck Dissection after RT  
 Yes 26 (26%)* 21 (16%)
 No 73 (74%) 110 (84%)
Chemotherapy dose-intensity 
delivered  
 < 85% 22 (22%) 29 (22%)
 ≥ 85% 77 (78%) 102 (78%)
*Two of these patients had their neck dissection after experiencing a severe late toxicity
Table 3. Types of late toxicity events seen by trial
91-11 97-03 99-14 Total
Feeding Tube Dependence  —* 29*  29
> 2 yrs. Post RT 
Grade 3+ Pharyngeal  16 28 19 63
Dysfunction (RTOG late 
toxicity criteria)
Grade 3+ Laryngeal  22 6 0 28
Dysfunction (RTOG late 
toxicity criteria)
Death 11 9 2 22
Other (e.g. infection, fistula) 3 0 1 4
Any    38** 40** 21** 99**
No Severe late toxicity  50 62 19 13
event (controls)
   * Feeding tube data were not collected at all in RTOG 91-11.
** Numbers do not always add up along columns, due to some patients having more than one 
 toxicity event.
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The pre-treatment characteristics of these 230 patients are shown in Table 
2, including both pre-treatment and treatment-related characteristics. 
Table 3 shows an accounting of the types of late toxicity events observed 
in this analysis; most were related to swallowing function (particularly in 
RTOG 97-03 and RTOG 99-14) or laryngeal dysfunction (RTOG 91-11). 
Patients with severe toxicities (cases) were more likely to be older and/or 
to have larger T-stage and/or larynx/hypopharynx primary cancer. On 
univariate analysis, there were no statistically significant differences in 
the rates of late effects based on each individual study/arm.
Univariate logistic regression analysis of pre-treatment and treatment-
related variables is shown in Table 4. Actuarial estimates of time to 
severe late toxicity as a function of T-stage, primary tumor site, and 
neck dissection are shown in Figures 2a to 2c, respectively. The most 
significant pre-treatment factor associated with severe late toxicity was 
age, analyzed as a continuous variable (p=0.0038) – older patients were 
significantly more likely to have severe late toxicity. T-stage (T3-4 more 
likely to have severe late toxicity) and tumor site (larynx/hypopharynx 
more likely to have severe late toxicity) were also statistically significant 
factors. On univariate analysis, none of the treatment-related variables 
were statistically significant except BED (p<0.0001), with a paradoxical 
negative association between BED and severe late toxicity. The p-value 
for potential association between severe late toxicity and neck dissection 
after RT was 0.145.
The results of a multivariable logistic regression model analysis are 
shown in Table 4. Age, T-stage and tumor site remained statistically 
significant. In addition, a positive association between post-treatment 
neck dissection and severe late toxicity was noted (p=0.02). Specifically, 
out of the 230 patients in this study, 47 (20%) underwent post-treatment 
neck dissection; this included 22% of the oral cavity/oropharynx patients 
and 19% of the larynx/hypopharynx patients. These 47 patients had a 
Case
Control
115 81 64 43 31 17
Pts. at Risk
11
0
25
50
75
100
0 12 24 36 48 60 72
Months From Randomization
%
 F
ai
le
d
113 93 79 38 5 0       0
Failed/Total 
Oral cavity/oropharynx     42 / 113 
Larynx/hypopharynx  55 / 115
Figure 2b. Time to Severe Late Toxicity by Primary Tumor Site 
Larynx/Hypopharynx cancer is associated with a statistically
non-significant higher likelihood of severe late toxicity (p value 
from Gray’s Test =0.076). 
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Figure 2a. Time to Severe Late Toxicity by T stage Advanced T 
stage is associated with a higher likelihood of severe late toxicity 
(p value from Gray’s Test =0.031). 
Figure 2. Time to Severe Late Toxicity Subgoup Analyses based 
on Patient/Treatment Characteristics 
(All graphs exclude 2 patients who had neck dissection after already 
experiencing a severe late toxicity.) 
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Figure 2c. Time to Severe Late Toxicity by Neck Dissection 
Neck dissection is associated with a statistically non-significant 
higher likelihood of severe late toxicity (p-value from Gray’s 
Test =0.09).
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crude rate of severe late toxicity of 55% (compared with 40% for the 183 
patients who did not undergo neck dissection).
Of note, besides neck dissection, other treatment-related factors were 
not associated with severe late effects. Although the most aggressive 
radiotherapy fractionation trial (RTOG 99-14, which used concomitant 
boost XRT + cisplatin) numerically had the highest crude rate of 
severe late toxicity (21/40 = 53%), there were no statistically significant 
differences among the trial arms.
As noted in Table 4, radiotherapy dose delivered (as analyzed as 
biologically equivalent dose [BED]) was significant on univariate analysis 
(with a paradoxical relationship in which lower RT dose was associated 
with higher risk) but fell out of the multivariable model.  The amount of 
chemotherapy delivered was not statistically significant in either model.
Discussion
This retrospective analysis of several prospective trials shows that the rate 
of severe late toxicity after CCRT for SCCHN is high, particularly with 
the analysis methodology used here. Specifically, in this study, patients 
with severe pre-treatment laryngopharynx dysfunction and patients 
with early tumor recurrence were excluded a priori from this analysis. 
Thus, the number of patients “at risk” for a severe late toxicity event 
is much smaller than the original treated population. This technique 
closely approximates the use of actuarial analysis of late complications, 
a technique which yields a higher rate of complications than simply 
reporting crude rate of complications, as reported by Bentzen et al.20 
A true actuarial analysis of late complications in head and neck cancer 
is difficult, because it is not easy to ascertain a date of onset of a late 
complication in any one individual patient (Figures 2a-2c). Our sample 
size of 230 patients makes this one of the largest studies of late toxicity in 
the concurrent chemoradiotherapy era. 
In this study, several factors that correlated with severe late toxicity were 
identified. Since this is a retrospective study, the data must be considered 
hypothesis-generating rather than definitive. Some caveats result from 
the fact that these studies were conducted over a 10-year time period 
(approximately 1991-2001), with variations in eligibility, treatment, and 
data collection techniques. A second problem inherent to retrospective 
studies like ours is that a number of potentially important factors may 
not have been collected at all. For example our database does not include 
information on tumor volume, cardiopulmonary co-morbidity, and 
amount of tobacco consumed in followup.
However, it is logical to believe that age, tumor site and tumor stage 
would predict for greater likelihood of severe late toxicity. The finding 
that post-treatment neck dissection was significantly associated with 
severe late toxicity was somewhat more surprising, although this has 
been reported previously. The number of patients undergoing post-
treatment neck dissection was relatively small (20%, despite over 50% 
of the patients having N2-3 disease), and thus these data can not be 
considered conclusive. It is possible that selection bias could lead to this 
association; for example, patients with larger volume neck disease may 
be more likely to undergo neck dissection and may be more likely to 
have neck-tumor-related damage to adjacent normal tissues unrelated 
to the neck dissection. It is possible, though, that disturbance of the soft 
tissues of the neck via post-treatment neck dissection could cause added 
swallowing dysfunction, for example by increasing fibrosis in the neck 
and thus limiting the mobility of the laryngopharynx. It should be noted 
that a similar report of an association between severe late toxicity and 
post-treatment neck dissection was recently reported by researchers at 
Table 4. Univariate and Multivariable Logistic Regression 
Models to Identify Covariates that are associated with 
severe late toxicity.
Univariate
Analysis
Multivariate
Analysis
Covariates
Odds
Ratio p-value
Odds 
Ratio
95% 
confidence 
Interval p value
Age 
 Continuous variable 1.043* 0.0038 1.05* [1.02,1.09] 0.001
Gender 
   Female RL
   Male 1.140 0.6846
Race 
   Non-Black RL
   Black 1.165 0.7458
KPS
   60-80 1.892 0.0612
   90-100 RL
Hemoglobin (gm%)
   Continuous Variable 1.005 0.9528
Weight loss (kg)
   Continuous Variable 1.018 0.3733
T Stage
   T1/T2 RL  RL
   T3/T4  2.041 0.0349 3.07 [1.444,6.54] 0.0036
N Stage
   NX/N0/N1 RL 
   N2 0.942 0.8464
   N3 1.297 0.6108
Tumor Site
   Oral cavity/oropharynx RL  RL
   Larynx/hypopharynx 2.955 0.0131 4.17 [1.57,11.03] 0.0041
BED (Toxicities) 
based on Actual 
Dose/Fx (Gy) 0.842 <0.0001
   Continuous Variable 
Neck dissection after RT**
   Yes 1.632 0.145 2.39 [1.16,4.92] 0.018
   No RL  RL
Percent of chemotherapy 
received relative to the 
protocol amount
   <  85% 1.033 0.9216
   ≥  85% RL
Abbreviations: RL=reference level; RT=radiation therapy
* The odds ratio of 1.043 for age indicates that for each one year increase in age, patients have 1.043 times 
higher odds of being in the case group (having a severe late toxicity) than being in the control group (not 
having a severe late toxicity).
** This excludes 2 patients who had neck dissection after having already experiencing a severe late toxicity.
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Fox Chase Cancer Center21.  If these findings are validated in additional, 
larger datasets, there may be important implications with respect to the 
controversy regarding neck dissection following chemoradiotherapy for 
patients with advanced neck disease.
The lack of significant association between cumulative radiotherapy dose 
delivery (or chemotherapy dose delivery) and severe late toxicity may 
be due to the narrow dose range prescribed and the generally excellent 
compliance. We are currently analyzing the detailed radiotherapy 
records (simulation films, dosimetry and treatment records) available at 
RTOG headquarters in order to estimate the doses received by individual 
normal tissue sub-structures within the head and neck. Several recent 
single-institution studies have rigorously analyzed the relationships 
between radiotherapy dose-volume-histograms for normal structures 
and the risk and severity of toxicities22, 23.
Considering the widespread acceptance of CCRT for SCCHN over the 
last 10 years, there are relatively few detailed studies of late toxicities. 
GORTEC reported long-term followup from their randomized trial of 
radiotherapy alone versus 5-FU/carboplatin/radiotherapy for oropharynx 
cancer; they did not find a significant difference in severe late toxicity24. 
However, there were fewer than 50 long-term survivors in that study. 
Staar reported that 51% of long-term survivors (> 2 years) after a very 
intense combination of accelerated fractionation radiotherapy and 
chemotherapy were dependent on feeding tubes8. With longer followup, 
that alarmingly high rate did decrease, and was not significantly worse 
than accelerated radiotherapy alone but the number of evaluable patients 
was relatively small25. Shiley reported that 4 of 13 (31%) cancer-free 
survivors (>1 year) after chemoradiotherapy required tube feedings for 
some or all of their nutrition26. 
These data suggest that the CCRT has reached the limits of acceptable 
long-term toxicity.  Dose intensity can not be easily increased without 
some new and effective technique(s) of protection against late effects. 
In the future, these may include modern techniques in radiotherapy 
technology27, 28, or biopharmacologic radioprotectors29-31. Presently, 
however, these techniques have only succeeded in reducing xerostomia, 
not severe late dysphagia. Emphasis should therefore be on careful 
patient selection for aggressive treatment and swallowing exercises before 
during and after radiotherapy32, 33.  Some patients may benefit from more 
invasive procedures, such as dilatation of hypopharyngeal/esophageal 
stricture under anesthesia.
For some patient subpopulations the risks of concurrent chemoradio-
therapy may outweigh the benefits. For example, subgroup analysis of a 
meta-analysis suggested that there was no significant survival benefit to 
CCRT in patients older than age 701. Our data may add to the controversy 
regarding management of the elderly patient with head and neck cancer 
– if there is no significant survival benefit and a significant increase in 
late toxicity with concurrent chemoradiotherapy, should it be the stan-
dard of care in this patient population?
Our study has several limitations that should be discussed. First, it is 
a “meta-analysis” of three separate clinical trials, each of which had 
somewhat different eligibility criteria, chemoradiotherapy regimen, and 
year of activation. However, all of the patients did receive treatment that 
would be considered appropriate standard of care in today’s oncology 
clinic. Second, our exclusion of patients with pre-existing severe 
laryngopharynx dysfunction from this analysis can be considered 
controversial. Although patients were excluded a priori, determining 
pre-existing severe laryngopharynx dysfunction is subjective. However, 
it should be noted that the determination of post-treatment severe 
laryngopharynx dysfunction (toxicity) is also subjective. It is extremely 
difficult to determine if severe dysfunction after treatment is the result of 
treatment or the result of the pre-existing cancer.  By excluding patients 
with pre-treatment severe laryngopharynx dysfunction, we attempted to 
isolate the influence of treatment on outcomes.  Third, our study is an 
exploratory analysis; while it is one of the larger series on late toxicity 
after chemoradiotherapy, the number of patients and number of events 
are relatively small. We plan to address this in the future with an analysis 
of the recently completed trial, RTOG 0129. This was a randomized trial 
of standard fractionation versus accelerated fractionation radiotherapy 
(with cisplatin in both arms). Preliminary acute and subacute toxicity 
data showed no significant differences between the two arms34. It is 
premature at this time to perform a detailed analysis of efficacy or late 
toxicity from that study. It is possible that with improved knowledge 
and experience with CCRT and supportive care available in the 21st 
century, outcomes may be improved in RTOG 0129 compared to
historical controls.
Ultimately, it should be remembered that for most patients with head 
and neck cancer, the highest priority is cure and length of survival35. 
Excessive concern about treatment toxicity should not prevent the use of 
proven aggressive multimodality treatment, provided the patient is well 
informed about the potential late sequelae of these aggressive treatment 
regimens.
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Clinical Research Studies/Grants
Phase I Study of Combination of Sorafenib and Radiation 
Therapy For The Treatment of Patients With Brain 
Metastases and Primary Brain Tumors
A Phase I Pilot Study of Samarium-153 Combined with 
Neoadjuvant Hormonal Therapy and Radiation Therapy in 
Men with Locally Advanced Prostate Cancer
A Phase I Study of Pemetrexed (Alimta) and Carboplatin 
and Radiation Therapy in Patients with Inoperable Non-
Small Cell Lung Cancer
A Phase I Study of Combination Chemo-radiotherapy with 
Biologic Therapy for Advanced Head and Neck Cancer 
[Bevacizumab IND #12,907] Original: 1/26/06; Revised 
3/24/06)
A Randomized, Phase III, Open-Label Study of Oral 
Topotecan Plus Whole Brain Radiation Therapy (WBRT) 
Compared with WBRT Alone in Patients with Brain 
Metastases From Non Small Cell Lung Cancer HYT105962, 
Division: Worldwide Development, Retention Category: 
GRS019, Protocol Amendment Number: 01, Compound 
Number: SK&F-104864, Effective Date: 11-Apr-2007; 
including a Topotecan Oral Investigator Brochure, 
Compound Number: SK&F-104864, Approved Name: 
Hycamtin, Effective Date: 13-Jul-2006, Version number:8 
dated July 2006
Prospective, Longitudinal, Multi-Center, Descriptive 
Registry of Patients Receiving Therapy Other Than Surgical 
Resection Alone for Newly Diagnosed Head and Neck 
Carcinoma.
A Phase 1, Open-Label, Dose-Escalation, Safety Study of 
the Combination of VELCADE and Chemoradiation for the 
Treatment of Patients with Cancer
A Phase II Evaluation of Dose-Painted IMRT in 
Combination with 5-Fluorouracil and Mitomycin-C 
for Reduction of Acute Morbidity in Carcinoma of the 
Anal Canal
A Randomized Prospective Active-controlled Study of 
the Epi-Rad90TM Opthalmic System for the Treatment of 
Subfoveal Choroidal Neovascularization Associated With 
Wet Age-related Macular Degeneration
•
•
•
•
•
•
•
•
•
A Phase IB, Open-Label, Dose-escalation Safety Study of the 
Combination of Sunitinib and Radiation for the Treatment 
of Patients with Cancer.
A Pilot Study Investigating Active Breathing Control (ABC) 
to Reduce Radiation Dose to Normal Structures in Breast 
Cancer Patients
A Randomized Trial Comparing Two Forms of 
Immobilization of the Head for Fractionated Stereotactic 
Radiotherapy
Phase I Dose Escalation Trial in Patients with Brain 
Metastases Using IMRT
Exploratory Study of the Efficacy of the Cone Beam 
Computed Tomography (CBCT) Scanning During Radiation 
Therapy for Tumors of the Head and/or Neck
A Phase III Protocol of Androgen Suppression (AS) and 
Radiation Therapy (RT) vs Androgen Suppression and RT 
Followed by Chemotherapy With Paclitaxel, Estramustine 
and Etoposide (TEE) for Localized, High Risk Prostate 
Cancer
Waterfall Plots After Stereotactic Radiotherapy for Acoustic 
Neuroma: Assessing Response With a Novel Metric of 
Treatment Efficacy
Stereotactic Fractionated Radiotherapy and Radiosurgery 
for the Treatment of Chordomas and Chondrosarchomas
Retrospective Study of Esophageal Cancer Patients Treated 
With Surgery, Radiation Therapy, Chemotherapy Or Any 
Combination of the Three At Thomas Jefferson University 
Hospital
Optimization of Radiation Therapy for Hypopharyngeal and 
Cervical Esophageal Cancers: A Comparison of Conventional 
and Three-dimensional Conformal Techniques
Retrospective Analysis of Radiation Dose to Optic 
Structures Using Fractionated Stereotactic Radiotherapy: 
Determination of a Dose/Volume Relationship to Guide 
Safe Treatment of Tumors Near the Optic Apparatus
Standardize Serum and Plasma Sample Collection and 
Cytokine Normal Values for RTOG Repository and 
Database
•
•
•
•
•
•
•
•
•
•
•
•
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Research
A Prospective Phase II Trial of Transperineal Ultrasound-guided 
Brachytherapy for Locally Recurrent Prostate Adenocarcinoma 
Following External Beam Radiotherapy – RTOG 0526
A Phase III Double Blind Placebo Controlled Study To Evaluate 
the Efficacy of Zometa for the Prevention of Osteoporosis and 
Associated Fractures In Patients Receiving Radiation Therapy 
and Long Term LHRH Agonists For High-grade and/or Locally 
Advanced Prostate Cancer – RTOG 0518
RTOG #0012:  A Randomized Phase II Trial of Preoperative 
Combined Modality Chemoradiation for Distal Rectal Cancer
RTOG #0024:  A Phase II Trial of Early Postoperative Paclitaxel 
Followed by Paclitaxel and Cisplatin Concurrent With Radiation 
Therapy for Resected, High-Risk Squamous Carcinoma of the 
Head and Neck
RTOG #0126:  A Phase III Randomized Study of High Dose 
3D-CRT in Patients Treated for Localized Prostate Cancer
RTOG #0129:  A Phase III Trial of Concurrent Radiation and 
Chemotherapy for Advanced Head and Neck Carcinomas
RTOG #0132: A Phase II Trial of Neoadjuvant/Adjuvant STI-571 
(Gleevec NSC #716051) for Primary and Recurrent Operable 
Malignant Gist Expressing the Kit Receptor Tyrosine Kinase 
(CD117) (ACRIN 6665)
RTOG #0211:  A Phase I/ Study of an Oral Epidermal Growth 
Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TK), ZD 
1839 (IRESSA) (NSC #715055) With Radiation Therapy in 
Gliblastoma Multiforme
RTOG #0214:  A Phase III Comparison of Prophylactic Cranial 
Irradiation in Patients with Locally Advanced Non-Small Cell 
Lung Cancer
RTOG #0225: A Phase II Study of Intensity Modulated Radia- 
tion Therapy (IMRT) +/- Chemotherapy for Nasopharyngeal 
Cancer
RTOG #0227:  A Phase I/II Study of Pre-Irradiation Chemo-
therapy with Methotrexate, Rituximab, and Temozolomide and 
Post-Irradiation Temozolomide for Primary Central Nervous 
System Lymphoma
RTOG #0232:  A Phase III Study Comparing Combined External 
Beam Radiation and Transperineal Interstitial Permanent 
Brachytherapy with Brachytherapy Alone for Selected Patients 
with Intermediate Risk Prostatic Carcinoma
RTOG #0233:  A Phase II Randomized Trial for Patients with 
Muscle-Invading Bladder Cancer Evaluating Transurethral 
Surgery and BID Irradiation Plus Either Paclitaxel and Cisplatin 
•
•
•
•
•
•
•
•
•
•
•
•
•
or 5 Fluorouracil and Cisplatin Followed by Selective Bladder 
Preservation and Gemcitabine/Paclitaxel/Cisplatin Adjuvant 
Chemotherapy
RTOG #0236:  A Phase II Trial of Stereotactic Body Radiation 
Therapy (SBRT) in the Treatment of Patients with Medically 
Inoperable Stage I/II Non Small Cell Lung Cancer
RTOG #0241:  A Phase I Study Of Irinotecan And Cisplatin In 
Combination With Twice Daily Thoracic Radiotherapy (45 Gy) 
or Once Daily Thoracic Radiotherapy (70 Gy) for Patients with 
Limited Stage Small Cell Lung Cancer
RTOG #0247:  A Randomized Phase II Trial of Neoadjuvant 
Combined Modality Therapy for Locally Advanced Rectal 
Cancer (Version: Activation 3/15/04)
RTOG #0320:  A Phase III Trial Comparing Whole Brain 
Radiation and Stereotactic Radiosurgery Alone Versus With 
Temozolomide or  Erlotinib in Patients with Non-Small Cell 
Lung Cancer and 1-3 Metastases 
RTOG #0415: A Phase III Randomized Study of Hypofraction-
ated 3D-CRT/IMRT Versus Conventionally Fractionated 3D-
CRT/IMRT in Patients with Favorable-Risk Prostate Cancer
RTOG #0420:  A Phase II Study of Radiation Therapy Plus 
Low Dose Temozolomide Followed by Temozolomide Plus 
Irinotecan for Glioblastoma Multiform
RTOG #0521:  A Phase III Protocol of Androgen Suppression 
(AS) and 3DCRT/IMRT vs. AS and 3DCRT/IMRT Followed by 
Chemotherapy with Docetaxel and Prednisone for Localized, 
High-Risk Prostate Cancer
A Randomized Phase III Trial of Concurrent Accelerated 
Radiation and Cisplatin Versus Concurrent Accelerated 
Radiation, Cisplatin, and Cetuximab (C225) [Followed by 
Surgery for Selected Patients] For Stage III and IV Head and 
Neck Carcinomas 
RTOG #0524: A Phase I/II Trial of a Combination of Paclitaxel 
and Trasuzumab with Daily Irradiation or Paclitaxel Alone with 
Daily Irradiation Following Transurethral Surgery for Non-
Cystectomy Candidates with Muscle Invasive Bladder Cancer
RTOG #0525: A Phase III Trial Comparing Conventional 
Adjuvant Temozolomide with Dose-Intensive Temozolomide 
in Patients with Newly Diagnosed Glioblastoma
RTOG #0611-Urinary VEGF and MMP levels in patients 
receiving radiation therapy for glioblastoma multiforme: 
Prospective determination of a predictive value for recurrence
•
•
•
•
•
•
•
•
•
•
•
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A Randomized Phase III Comparison of Standard-Dose 
(60Gy) Versus High Dose (74Gy) Conformal Radiotherapy 
with Concurrent and Consolidation Carboplatin/Paclitaxel 
in Patients with Stage IIIA/IIIB Non Small Cell Lung Cancer; 
RTOG #0617/NCCTG N0628/CALGB 30609; Version Date: 
August 1, 2007; Updated Date: November 27, 2007; Activation 
Date: November 27, 2007
RTOG #9003: A Phase III, Randomized Study to Compare 
Twice Daily Hyperfractionation, Accelerated Hyperfractionation 
With a Split and Accelerated Fractionation With Concomitant 
Boost to Standard Fractionation Radiotherapy for Squamous 
Cell Carcinomas of the Head and Neck
RTOG #9019: A Phase III Study of the Treatment of Pathologic
Stage C Carcinoma of the Prostate with Adjuvant 
Radiotherapy
RTOG #9202:  A Phase III Trial of the Use of Long-Term Total 
Androgen Suppression Following Neoadjuvant Hormonal 
Cytoreduction and Radiotherapy in Locally Advanced 
Carcinoma
RTOG #9403:  A Postoperative Evaluation of 5-FU By Bolus 
Injection vs. 5-FU By Prolonged Venous Infusion Prior to 
and Following Combined Prolonged Venous Infusion + Pelvis 
XRT vs. Bolus 5-FU + Leucovorin + Levamisole Prior to and 
Following Combined Pelvic XRT +Bolus 5-FU + Leucovorin in 
Patients with Rectal Cancer, Phase III
RTOG #9406:  A Phase I/II Dose Escalation Study Using 
Three Dimensional Conformal Radiation Therapy for 
Adenocarcinoma of the Prostate
RTOG #9408:  A Phase III Trial of the Study of Endocrine 
Therapy Used as a Cytoreductive and Cytostatic Agent Prior 
to Radiation Therapy in Good Prognosis Locally Confined 
Adenocarcinoma of the Prostate
RTOG #9410:  A Three-Arm, Phase III Study of Concomitant 
vs. Sequential Chemotherapy and Thoracic Radiotherapy for 
Patients With Locally Advanced Inoperable Non-Small Cell 
Lung Cancer
RTOG #9413:  A Phase III Trial Comparing Whole Pelvic 
Irradiation Followed by a Conedown Boost to Boost Irradiation 
Only and Comparing Neoadjuvant to Adjuvant Total Androgen 
Suppression (TAS)
RTOG #9501:  A Phase III Intergroup Trial of Surgery Followed 
by Radiotherapy vs. Radiochemotherapy for Resectable High 
Risk Squamous Cell Carcinoma of the Head and Neck
RTOG #9512:  A Randomized Study of Hyper-Fractionation vs. 
Conventional Fractionation in T2 Squamous Cell Carcinoma of 
the Vocal Cord
•
•
•
•
•
•
•
•
•
•
•
RTOG #9601: A Phase III Trial of Radiation Therapy With or 
Without Casodex in Patients with PSA Elevation Following 
Radical Prostatectomy for pT3NO Carcinoma of the Prostate
RTOG #9703:  A Randomized, Phase II Trial of Concurrent 
Radiation and Chemotherapy for Advanced Squamous Cell 
Carcinomas of the Head and Neck
RTOG #9708: A Phase II Study of Adjuvant Postoperative 
Irradiation Combined With Cisplatin/Taxol Chemotherapy 
Following TAH/BSO for Patients With High-risk Endo-
metrial Cancer
RTOG #9712:  A Phase I/II Dose Escalation Study of Thoracic 
Irradation with Concurrent Chemotherapy for Patients with 
Limited Small Cell Lung Cancer
RTOG #9801: A Phase III Study of Amifostine Mucosal 
Protection for Patients With Favorable Prognosis Inoperable 
Stage II-IIIA/B Non-Small Cell Lung Cancer (NSCLC) Receiving 
Sequential Induction and Concurrent Hyperfractionated 
Radiotherapy for Paclitaxel and Carboplatin
RTOG #9802:  A Phase II Study of Observation in Favorable 
Low-Grade Glioma and a Phase III Study of Refraction 
with or without PCV Chemotherapy in Unfavorable Low-
Grade Glioma
RTOG #9803:  A Phase I/II Dose Escalation Study Applying 
Conformal Radiation Therapy in Supratentorial Glioblastoma 
Multiforme
RTOG #9805:  A Phase II Trial of Transrectal Ultrasound 
Guided Permanent Radioactive Implantation of the Prostate 
for Definitive Management of Localized Adenocarcinoma of 
the Prostate
RTOG #9811:  A Phase III, Randomized Study of 5-FU, 
Mitomycin-C and Radiotherapy vs. 5-FU, Cisplatin and 
Radiotherapy in Carcinoma of the Anal Canal
RTOG #9813:  A Phase I/III Randomized Study of Radiation 
Therapy and Temozolomide vs. Radiation Therapy and BCNU 
for Anaplastic Astrocytoma
RTOG #9906: A Phase I/II in Patients With Muscle-Invading 
Bladder Cancer of Transurethral Surgery Plus Taxol, 
Cisplatin and BID Irradiation Followed by Either Selective 
Bladder Preservation or  Radical Cystectomy and Adjuvant 
Chemotherapy
RTOG #9910:  A Phase III Trial to Evaluate the Duration 
of Neoadjuvant Total Androgen Suppression and Radiation 
Therapy in Intermediate-Risk Prostate Cancer
•
•
•
•
•
•
•
•
•
•
•
•
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RTOG #0235: Positron Emission Tomography Pre and Post 
Treatment Assessment for Locally Advanced Non Small Cell 
Lung Cancer (ACRIN #6668)
RTOG #0413:  A Randomized Phase III Study of Conventional 
Whole Breast Irradiation (WBI) versus Partial Breast Irradiation 
(PBI) for Women with Stage 0, I, II Breast Cancer (NSABP B-39)
RTOG #0615: Phase II Study of Concurrent Chemoradio-
therapy using Three-Dimensional Conformal Radiotherapy 
(3D-CRT) or Intensity-Modulated Radiation Therapy (IMRT) 
+ Bevacizumab (BV) for Locally or Regionally Advanced 
Nasopharyngeal Cancer
RTOG #0019:  A Phase II Study of External Beam Radiation 
Therapy Combined With Permanent Source Brachytherapy for 
Intermediate Risk Clinically Localized Adenocarcinoma of the 
Prostate
RTOG #0212:  A Phase II/III Randomized Trial of Two Dose 
Schedules for Delivering Prophylactic Cranial Irradiation for 
Patients with Limited Disease Small Cell Lung Cancer
A Phase II Randomized Trial of Surgery Followed by 
Chemoradiotherapy Plus C225 (CETUXIMAB) for Advanced 
Squamous Cell Carcinoma of the Head and Neck
A Phase III Trial for Locally Recurrent, Previously Irradiated 
Head and Neck Cancer: Concurrent Re-Irradiation and 
Chemotherapy Versus Chemotherapy Alone
RTOG #0424: A Phase II Study of a Temozolamide-Based 
Chemoradiotherapy Regimen for High Risk Low-Grade 
Gliomas
A Phase II Trial of Preoperative Chemotherapy and 
Chemoradiotherapy for Potentially Resectable Adenocarcinoma 
of the Stomach
Basic Research Studies/Grants
Improvement of Tumor Control by Combining an Inhibitor 
of the Epidermal Growth Factor Receptor (EGFR) with 
Radiation Therapy
A New Role of MEPE/OF45 as a Co-factor of CHK1 for DNA 
Damage Response
A New Target for Preventing Breast Cancer Metastasis to Bone
The Mechanism of Excess Relative Risk on Carcinogenesis 
Induced High Let Radiation
ACRIN Protocol 6688: PET Pre- and Post Treatment Assessment 
for Locally Advanced Non-Small Cell Lung Carcinoma
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Ethyl Pyruvate As A Radiation Mitigator – In Vivo Character-
ization And Mechanistic Studies
Multichannel Robotic System for Concurrent Delivery and 
Immobilization of Interstitial Therapeutic Agents
Molecular Determinants of Glioblastoma Response to ZD6474 
Combined With Radiotherapy And Temozolamide
Improvement of Fractionated Radiation Therapy by Combin-
ation with SU11248 - Impact of Scheduling
Molecular Determinants of Glioblastoma Response to AZD2171 
Combined with Radiotherapy and Temozolamide
Molecular Determinants of Glioblastoma Response to BAY 
43-9006 (Sorafenib) Combined with Temozolamide and 
Radiotherapy
RTOG Research Associates Committee Chair
RTOG Group Member Agreement
Fused MR-Based Imaging Datasets Improving Surgical 
Outcomes and Providing Superior Response Classification 
System of Malignant Gliomas
Translational Research Studies/Grants
Clinical Utility of Biomarkers for Stage III Non-small Cell Lung 
Carcinoma and Stage IV Head and Neck Cancer
Checkpoint Reduced Cell Sensitivity to High Energy Particles-
Induced Killing
Characterization of the Role of Fhit In Maintenance of Genomic 
Integrity Following Low Dose Radiation, In Vivo and In Vitro
Modification of Hyperthermia Response:  Project 1 “Sensi-
tization to Thermoradiotherapy in Human Melanoma 
Xenografts”
Modification of Hyperthermia Response:  Core B “Administration”
Radiation Therapy Oncology Group Committee Chair
Modulation of Radiosensitivity in zebrafish
Radiation Therapy Oncology Group Physicist Chair
An Emerging Technology Assessment Mechanism for RTOG 
Protocols
Modification of Hyperthermia Response:  Project 3 “Reduced 
pHi Inhibits Heat-Induced HSP, Enhances Apoptosis”
Modification of Hyperthermia Response:  Core A “Intracellular 
pH Regulation”
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
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Deputy Group Chair of the Radiation Therapy Oncology Group
Protection from Dose Limiting Toxicity of Chemoradiation for 
Head and Neck Cancer
Improvement of Tumor control by Combining a VEGF Blocker, 
VEGF-Trap, with Radiation Therapy
Molecular Signatures related to Amifostine Radioprotection
Evaluation of Fullerene Nanoparticles in a Zebrafish Model
Microenvironmental control of the Radiation Response
Vice Chair Translational Research Program
Nutrigenomics for the Study of Disease Prevention and Intervention
Protection from Dose Limiting Toxicity of Chemoradiation for 
Head and Neck Cancer
Health Research Formula Fund Grant Project 1: Clinical Utility 
of Biomarkers for Stage III Non-small Cell Lung Carcinoma 
and Stage IV Head and Neck Cancer
Enhancement of Tumor Response to Radiation by Use of 
Vascular Targeting Agent, ZD6126
Conducting Biomarker, and Proteomics Correlative Research 
in the Radiation Therapy Oncology Group
Microenvironmental Control of the Radiation Response After 
ERBITUX Blockade
Improvement of Colorectal Tumor Control by Combining 
ERBITUX with Radiotherapy and Chemotheraputic Agents 
Oxaliplatin and Irinotecan (CPT-11) PCGA 04-001
Improvement of Brain Tumor Control by Combining 
ERBITUX with Radiotherapy and Chemotherapeutic Agents 
Temozolamide (CPT-11) PCGA 04-025
Orthogonal Ultrasound for Cancer Detection and Therapy
Sono-Contrast Induced Functional Imaging/Spectroscopy
Robot-Assisted Platform for Intratumoral Delivery
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
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Support Groups
Jefferson Kimmel Cancer Center Support Groups, October – December 2008
October
4 A Place for Me 
A program for children whose parent or grandparent has 
cancer. Using art, games and other activities, 
children are helped to understand and to cope with the 
diagnosis of cancer in the family.  A separate group for 
parents or grandparents is held concurrently.
Time: 10 am – 1:30 pm
Location: Bluemle Life Sciences Building
15  The Delaware Valley Brain Tumor 
Support Group  
Time: 7 – 8:30 pm
Location: Bluemle Life Sciences Building, Suite 105
17   Brain Tumor Caregiver Workshop  
Time: 8 am – 4 pm
Location: Bluemle Life Sciences Building, Suite 101
23   Facing Breast Cancer   
Screening and Detection 
Barbara C. Cavanaugh, MD, Breast Imaging
Time: 12 – 1:30 pm
Location: Hamilton Building, Suite 505
25   Navigating the New Normal   
(for young adult cancer survivors, ages 18-45) 
Cartoon Boot Camp
Christian “Patch” Patchell, Graphic Artist
Time: 2 – 5 pm
Location: Hamilton Building, Suite 210/211
30   Current Topics   
End-of-Life Issues 
Anne Delengowski, RN, MSN, AOCN
Time: 12 – 1:30 pm
Location: Hamilton Building, Suite 505
November
3   Look Good…Feel Better 
A free program for women who are undergoing cancer 
treatment to learn to cope with appearance-related side 
effects of treatment.
Time: 1:30 – 3:30 pm
Location: Gibbon Building, 2nd Floor, Suite 2135
6  Survivor’s Conference   
Life After a Cancer Diagnosis
A patient and family conference on all issues
relating to cancer survivorship.
Time: 3:30 – 7 pm
Location: Bluemle Life Sciences Building
13   Current Topics  
Lung Cancer Awareness Month Program
Benny Weksler, MD, Division of Cardiothoracic Surgery, 
Section of Thoracic and Foregut Surgery
Time: 12:00 – 1:30 pm
Location: Hamilton Building, Suite 505
19   The Delaware Valley Brain Tumor 
Support Group 
Group for individuals diagnosed with a brain tumor and 
their families. Patients and families share information, 
gain insight and develop coping strategies to face the 
challenges associated with living with a brain tumor. For 
more information, call 215-955-4429.
Time: 7 – 8:30 pm
Location: Bluemle Life Sciences Building, Suite 105
20   Current Topics   
Jefferson Journaling: A Program for Women Facing 
Cancer, Janet Ruth Falon
Time: 12:00 – 1:00 pm
Location: Kimmel Cancer Center
 Bodine Building, Suite G-312
December
3  Navigating the New Normal   
(for young adult cancer survivors, ages 18-45).  Holiday 
Happy Hour – an opportunity to network with other 
survivors your age. $3.00 drink specials, free appetizers and 
live music (non-alcoholic drinks also available). Friends, 
partners and other supports are welcome to attend.
Time: 6 – 8 pm
Location: Doc Watson’s Pub, 216 S. 11th Street
 2nd Floor
11  Man to Man  
PSA Rising Post-Treatment 
Leonard G. Gomella, MD
Chair and Professor, Department of Urology
Time: 12:00 – 1:30 pm
Location: Bluemle Life Sciences Building, Suite 101
17  The Delaware Valley Brain Tumor 
Support Group  
Time: 7:00 – 8:30 pm
Location: Bluemle Life Sciences Building, Suite 105
Ongoing Programs
Every Thursday   
Radiation Therapy Information Session 
Time: 10 – 11:00 am
Location: Kimmel Cancer Center – Bodine, Suite G-312
 Learning to Live Better with the Stress of Cancer Research 
Study
Free 8-week cancer support programs for women, 
21 years or older, and diagnosed with cancer or 
recurrence within three years. Call 215-955-2881 or 
1-800-JEFF-NOW, or visit: www.JeffersonHospital.org/
cim and click on the study poster.
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Answering the need that exists for a single reference to 
address the practical issues of implementing image guided 
radiation therapy (IGRT) into prostate cancer treatment, 
this text provides: 
   • complete overview of new and exciting technologies 
   • practical guidance on successfully employing IGRT to 
improve patient outcomes 
   • disease stage-specific recommendations which include 
dosage, fractionation, target volume delineation, and 
tissue tolerances 
   • latest novel approaches to radiotherapy of prostate 
cancer that include intensity modulated radiation 
therapy (IMRT), hypofractionated radiation therapy, 
and proton beam radiation therapy
Contents Include: 
   •  Overview and treatment guidelines for image-guided
treatment in prostate cancer management 
   •  Imaging modalities 
   •  Modeling potential benefits from IGRT 
   •  Pelvic and prostate anatomy, implications for IGRT 
   •  Image-guided treatment planning and localization 
modalities 
   • Image-guidance: the urologist perspective 
   • IGRT in prostate cancer: focus on fiducials 
   • IGRT in prostate cancer: focus on BAT and ultrasound 
   • IGRT in prostate cancer: focus on adaptive therapy 
   •  IGRT in postoperative RT for prostate cancer 
   • The use of image-guidance in prostate brachytherapy 
   •  IGRT in prostate cancer: targeting pelvic lymph nodes 
   • Fractionation issues with IGRT for clinically localized 
prostate cancer 
   • Image-guided proton beam radiotherapy 
   • Future developments: On-line dosimetric verification 
and cone-beam RT planning and verification 
Image-guided Radiation 
Therapy For Prostate Cancer: 
Principles And Practice
An outstanding new title
from Informa Healthcare
Richard K. Valicenti 
Thomas Jefferson University Hospital 
Philadelphia, Pennsylvania, U.S.A.
Adam P. Dicker 
Thomas Jefferson University Hospital 
Philadelphia, Pennsylvania, U.S.A.
David A. Jaffray
Princess Margaret Hospital, Toronto
Ontario, Canada
May 2008 / ISBN-13: 9781420060782 
312 pp. / 158 Illustrations / Price: $229.95
Ordering Information 
PHONE  North America 1-800-634-7064 
 South America 1-859-727-5000 
 Int’l +44 (0) 1264 343071 
FAX  North America 1-800-248-4724
 South America 1-859-647-4028
 Int’l +44 (0) 1264 343005 
E-MAIL  orders@taylorandfrancis.com 
INTERNET  www.amazon.com or www.bn.com 
MAIL  Informa Healthcare
 Kentucky Distribution Center
 7625 Empire Drive
 Florence, KY 41042 U.S.A.
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